Stockwinners Market Radar for April 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EDT Hutchmed announces NDA acceptance for Fruquintinib in China - HUTCHMED "announces that its New Drug Application for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma in China has been accepted for review by the China National Medical Products Administration."

20:20 EDT Cathie Wood's ARK Investment bought 484K shares of Roblox today

20:18 EDT Mister Car Wash names Mary Porter as Chief People Officer - Mister Car Wash announced the appointment of Mary Porter as Chief People Officer. Mary will be responsible for developing and implementing the company's human resources strategy, including talent acquisition, employee engagement, payroll, and organizational development.

17:55 EDT Patrick Industries CFO Jake Petkovich to step down, Filer named interim CFO - Patrick Industries announced that Jake Petkovich, Executive Vice President of Finance, CFO and Treasurer, will step down in May to accept a senior leadership position with another company. Petkovich, who has served as CFO of Patrick since November 2020, will remain in his current position until that time and provide support to ensure an orderly transition. In alignment with the company's executive succession plan, the Board of Directors has approved the appointment of Matthew Filer as Interim CFO, effective upon Petkovich's departure in May.

17:53 EDT Patrick Industries CFO Jake Petkovich steps down, Matthew Filer now interim CFO - Patrick Industries announced that Jake Petkovich, Executive Vice President of Finance, CFO and Treasurer, will step down in May to accept a senior leadership position with another company. Petkovich, who has served as CFO of Patrick since November 2020, will remain in his current position until that time and provide support to ensure an orderly transition. In alignment with the company's executive succession plan, the Board of Directors has approved the appointment of Matthew Filer as Interim CFO, effective upon Petkovich's departure in May.

17:31 EDT Take-Two Chairman Zelnick sells $8.3M in company shares - Take-Two Chairman Strauss Zelnick disclosed in a regulatory filing that he had sold 68,351 shares of company stock at $122.12 per share on April 13 for a total transaction amount of $8,347,154

17:09 EDT Nektar Chief Medical Officer Brian Kotzin, CFO Jillian Thomsen to step down - As part of the reorganization initiative, Nektar "also announced several changes to its executive team: Dr. Brian Kotzin, Nektar's Chief Medical Officer, will be stepping down from his full-time role but will continue to serve in an ongoing role as a strategic advisor to the company. Dr. Mary Tagliaferri, current Chief Development Officer, will assume the role of Chief Medical Officer. Jillian Thomsen will be stepping down from her role as Chief Financial Officer (CFO) and will depart the company in June following a transition period. The company has appointed Sandra Gardiner to the role of acting CFO. Sandra is a skilled business and finance executive with over 30 years of financial and accounting experience. She is a partner at FLG Partners, a leading CFO services firm in Silicon Valley. Kevin Brodbeck, Nektar's SVP of Technical Operations, will depart the company in June following a transition period. Ken Franke, current VP of Biologics Development & Manufacturing will assume Kevin's responsibilities."

17:04 EDT Wrap Technologies CEO TJ Kennedy steps down, Kevin Mullins to succeed - Wrap Technologies announced the immediate appointment of Kevin Mullins as CEO. In connection with Mullins' appointment, TJ Kennedy has agreed to immediately step down as Wrap's CEO and a member of the Board of Directors. Mullins, who joined Wrap's leadership team as President in April 2022, possesses extensive experience as an executive and advisor in the public safety solutions market and has a successful track record of taking companies from inception to growth to profitability. In addition to having the confidence and trust of Wrap's employees and customers, he has led many of the company's initial cost containment initiatives, recruiting and operations efforts, and large customer acquisitions over the past year.

17:01 EDT Flotek receives noncompliance notice from Nasdaq - Flotek announced it has received written notice from the New York Stock Exchange that the average closing price of the Company's shares of common stock was below $1.00 per share over a period of 30 consecutive trading days, which is below the requirement for continued listing on the NYSE.

17:00 EDT Ryvyl initiates spin-off its stablecoin technology coyni - "We also just initiated the spin-off of coyni, our stablecoin technology, into a publicly traded vehicle that will assist in our broad value creation strategy by means of a special dividend to be paid upon completion of the spin-off. We have already identified and expect to acquire the proper vehicle in the coming weeks to proceed with the spin-off and we believe unlock significant shareholder value. We have also identified the investment banking team for the transaction and are in the process of evaluating mergers with possible partners. With a growing pipeline in our domestic and international acquiring businesses, market share capture in American Samoa, recent breakthrough sign ups with our banking-as-a-service solution, and plans to spin-off coyni to unlock its potential, we are well positioned for strong growth and expansion of our presence in the digital payments landscape. In 2023, we expect to see our transaction volume increase to $6 billion resulting in revenue of $60 million and a positive adjusted EBITDA of $4M," said the company along with quarterly results.

16:46 EDT F&M Bank announces investment in Fort Wayne, Indiana - F&M Bank announced strategic downtown growth in the Fort Wayne, Indiana market. Construction is underway on a regional headquarters located at 128 Wayne Street in downtown Fort Wayne. This new regional facility will include a new full-service bank office, a drive-up ATM, and 3,000 square feet of office space. This will be the third Fort Wayne area location for F&M, which currently has offices located on Illinois Road and Lima Road. The company announced the hiring of several new team members that will help expand F&M's brand throughout the Fort Wayne market. Joining F&M are Rob Slusser (Senior VP Market President), Dana Snyder (VP Commercial Banker), and Brian Ternet (Senior VP Commercial Banker). They join Andy Baker, Senior VP Regional President, and F&M Bank Commercial Banker, Curtis Metz.

16:41 EDT Fluor's joint venture awarded contract by U.S. DOE - Fluor announced that the U.S. Department of Energy, or DOE, selected Hanford Tank Waste Operations & Closure, a joint venture led by a subsidiary of BWX Technologies, with Fluor and Amentum, to execute the Hanford Integrated Tank Disposition Contract. The new contract has an estimated ceiling of $45B over a 10-year ordering period for environmental management operations at the Hanford Site in Washington state. The contract scope includes operation of Hanford tank farm facilities, eventual operation of the Waste Treatment and Immobilization Plant, and responsibility for other core functions such as project management, security and emergency services, business performance, and environment, safety, health and quality. The Hanford Site is a decommissioned nuclear production complex operated by the U.S. federal government on the Columbia River in Benton County, Washington.

16:40 EDT Avangrid, NTUA announce plans for green energy projects - Avangrid and the Navajo Tribal Utility Authority announced they have signed a Memorandum of Understanding to explore opportunities to develop up to 1 GW of green energy projects within the Navajo Nation in the states of New Mexico and Arizona. This partnership will allow the two parties to collaborate and study the feasibility of developing wind and solar projects, as well as battery storage solutions, to create new jobs, create economic development on the Navajo Nation, offset lost revenue on the Navajo Nation, and bring reliable, affordable, and renewable energy to power Navajo Nation businesses and residents. "We are thrilled to announce this collaboration with the NTUA, which allows us to join efforts to study and develop green energy projects with the potential of bringing important benefits to the region", said Pedro Azagra, CEO of AVANGRID. "Partnerships like these reflect our steadfast commitment to making a meaningful, positive impact in the lives of the families in the communities where we are present."

16:32 EDT Innoviva's sulbactam-durlobactam recommended for approval by FDA panel - Innoviva announced that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval based on a favorable benefit-risk assessment of sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The sulbactam-durlobactam New Drug Application (NDA), filed by Entasis Therapeutics Inc., a wholly owned subsidiary of Innoviva, was accepted and granted Priority Review by the FDA in November 2022, with a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2023. "The Committee's unanimous recommendation in favor of sulbactam-durlobactam, the first pathogen-targeted therapy for Acinetobacter, moves us closer to potentially addressing the urgent need for new treatment options for patients with serious and life-threatening infections caused by this pathogen," said David Altarac, MD, Chief Medical Officer, Entasis Therapeutics, a wholly owned subsidary of Innoviva. "We appreciate the Committee's thoughtful deliberation and strong vote of confidence, and look forward to working with the FDA as it completes its review."

16:31 EDT MSG Entertainment to sell majority interest in Tao Group Hospitality - Madison Square Garden Entertainment "announced that it has agreed to sell its 66.9% majority interest in Tao Group Hospitality to Mohari Hospitality, a global investment company focused on the luxury lifestyle and hospitality sectors, in a transaction that values Tao Group Hospitality at $550M. The transaction is expected to close in May. Upon completion of the sale of its majority interest, MSG Entertainment expects to receive net cash proceeds of approximately $300M."

16:24 EDT Guidewire names Michael Howe chief product officer - Guidewire announced the appointment of Michael Howe as Chief Product Officer, reporting to Chief Executive Officer Mike Rosenbaum. In this new role, Howe will lead product strategy, product management, product marketing and the Guidewire partner marketplace. "I am thrilled to welcome Michael Howe to the Guidewire management team. His deep enterprise software experience and insurance domain knowledge will help us hone our product strategy and innovation velocity," said Guidewire CEO Mike Rosenbaum. "There has never been a more exciting time for technology-driven innovation in the insurance industry and Michael's experience and leadership will accelerate our ability to foster industry-wide transformation."

16:17 EDT Gamida Cell's Omisirge therapy receives FDA approval - Gamida Cell announced that the U.S. Food and Drug Administration has approved Gamida Cell's allogeneic cell therapy, Omisirge, for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection. Omisirge received breakthrough therapy designation, priority review and orphan drug designation from the FDA, reflecting the unmet need for additional donor sources for stem cell transplant. It is the first allogeneic stem cell transplant therapy to be approved on the basis of a global, randomized Phase 3 clinical study. Please see the accompanying full Prescribing Information for more information. "FDA approval of Omisirge is a major advancement in the treatment of patients with hematologic malignancies that we believe may increase access to stem cell transplant and help improve patient outcomes," said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell. "We are grateful to all the clinicians, patients and the entire Gamida Cell team without whom this approval would not have been possible. We also acknowledge the key role the FDA has played in supporting the development of Omisirge and other innovative and potentially life-saving cell therapies for patients with cancer and other serious diseases."

16:13 EDT Erytech Pharma receives approval from Nasdaq to transfer listing - Erytech announced that it received approval from Nasdaq to transfer the listing of its American Depositary Shares representing ordinary shares of the company from Nasdaq Global Select Market to Nasdaq Capital Market. The transfer became effective at the opening of business on April 14. The company's ADSs continue to trade under the symbol (ERYP) and trading of its ADSs will be unaffected by this transfer. The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Select Market. The approval was based upon the company meeting the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on the Capital Market, except for the bid price requirement, the company's written notice of its intention to cure the deficiency by effecting a reverse stock split, if necessary, its agreement to the conditions outlined in the Nasdaq listing agreement, and additional supporting information provided in its application. In connection with the transfer to the Nasdaq Capital Market, Nasdaq granted the company an additional 180-day period to regain compliance with the requirement set forth in Nasdaq Listing Rule 5450 that the bid price of the company's ADSs meet or exceed $1.00 per ADS for at least ten consecutive business days. If at any time during this additional time period the closing bid price of the company's security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed.

16:08 EDT Middlesex Water to begin $11.1M initiative to upgrade drinking water in May - Middlesex Water has announced that beginning in May, it will begin an $11.1M initiative to upgrade drinking water infrastructure in the Borough of Carteret, New Jersey and portions of the community of Port Reading in Woodbridge, New Jersey. Under this annual initiative known as Renew, Middlesex intends to replace 26,000 linear feet of water main, as well as service lines, valves and fire hydrants. Concurrently, Middlesex will be implementing its "Knocking Out Lead" program to remove any lead or galvanized steel service lines it encounters. While treated water delivered by Middlesex to customers is lead free, as water travels through a lead service line, the corrosion of a pipe can add lead into the treated water delivered to customers. New Jersey legislation signed into law on July 22, 2021, requires investor owned and municipal water utilities to replace all utility owned and customer owned lead and galvanized steel service lines by 2031. While the company removed all of its known lead lines several decades ago, the legislation enables Middlesex to help customers address lead on their private property and the portion of the service line they own. As new mains are installed, any lead and galvanized service lines will be replaced with copper service lines at no direct cost to the property owner or tenant.

16:06 EDT Splunk names Min Wang as Chief Technology Officer - Splunk "announced Min Wang as Chief Technology Officer, effective immediately. Reporting to Tom Casey, SVP, Products & Technology, Wang will partner with leaders across Engineering, Product Management, Design and Go-to-Market teams to advance the vision and technical direction of Splunk's product portfolio innovation so customers can develop greater digital resilience."

16:04 EDT Avenue Therapeutics provides update from Type C meeting with FDA for Tramadol - Avenue Therapeutics announced that it has received official meeting minutes from the Type C meeting with the FDA conducted on March 9, regarding the development of intravenous Tramadol for the treatment of post-operative pain. The purpose of this meeting was to discuss and reach agreement with the FDA on the proposed study protocol that would assess the risk of opioid-induced respiratory depression related to opioid stacking on IV Tramadol compared to IV morphine. As disclosed in September 2022, Avenue received meeting minutes from the FDA regarding a Type A meeting conducted on August 9, 2022, for IV Tramadol. At that meeting, Avenue presented a study design for a single safety clinical trial that the company believes could address the concerns regarding risks related to opioid stacking and the FDA stated that the proposed study design appeared reasonable and agreed on various study design aspects with the expectation that additional feedback would be provided to Avenue upon review of a more detailed study protocol. Subsequent to the August 9 meeting, the company incorporated the FDA's suggestions from the meeting minutes and submitted a Type C Meeting Request and a briefing book that included a detailed study protocol as the basis for further discussion with the FDA on the requirements for a complete response to the second Complete Response Letter for IV Tramadol. The Type C meeting minutes from the FDA indicate that the FDA and Avenue Therapeutics are in agreement with a majority of the proposed protocol items and are in active discussion about remaining open items. The minutes indicate that the FDA also agrees that a successful study will support the submission of a complete response to the second Complete Response Letter for IV Tramadol pending final agreement on a statistical analysis plan and a full review of the submitted data in the complete response as well as concurrence from the Division of Anesthesia, Analgesia and Addiction Products, or DAAAP.

16:03 EDT Ancora urges Algonquin to accelerate divestitures after Kentucky termination - Ancora Holdings, which together with its affiliates is "a meaningful shareholder" of Algonquin Power & Utilities Corp., issued the following statement regarding the company's decision to terminate its stock purchase agreement with Kentucky Power Company and AEP Kentucky Transmission Company: "We are pleased that Algonquin has decided to terminate this poorly-conceived transaction following months of widespread pushback from shareholders. Given that Algonquin's stock price has declined by approximately 45% over the past 12 months and stagnated over the longer term, leadership needs to establish momentum and execute on its previously disclosed plan to sell $1 billion in assets. The company's disappointing long-term results and today's extremely challenging market environment should compel the Board of Directors to keep its foot on the gas. Ancora - and presumably many other shareholders - believe that the transaction's termination should not provide the company 'more flexibility' to delay asset sales. To the contrary, Algonquin should promptly execute these asset sales in order to refocus Algonquin's portfolio, delever the balance sheet, regain investor confidence and restore the company's trading multiple. Failure to do so will send a signal to the market that Algonquin is set on maintaining an unsustainable capital allocation policy and, in turn, likely result in shareholder intervention to put the company on a path to long-awaited value creation."

16:01 EDT Ancora urges Algonquin board to accelerate divestitures - Ancora Holdings Group, which is a meaningful shareholder of Algonquin Power & Utilities Corp. (AQN), issued the following statement regarding the Company's decision to terminate its stock purchase agreement with Kentucky Power Company and AEP Kentucky Transmission Company (AEP). Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora, and James Chadwick, President of Ancora Alternatives LLC, commented: "We are pleased that Algonquin has decided to terminate this poorly-conceived Transaction following months of widespread pushback from shareholders. Given that Algonquin's stock price has declined by approximately 45% over the past 12 months and stagnated over the longer term, leadership needs to establish momentum and execute on its previously disclosed plan to sell $1 billion in assets. The Company's disappointing long-term results and today's extremely challenging market environment should compel the Board of Directors to keep its foot on the gas. Ancora - and presumably many other shareholders - believe that the Transaction's termination should not provide the Company "more flexibility" to delay asset sales.1 To the contrary, Algonquin should promptly execute these asset sales in order to refocus Algonquin's portfolio, delever the balance sheet, regain investor confidence and restore the Company's trading multiple. Failure to do so will send a signal to the market that Algonquin is set on maintaining an unsustainable capital allocation policy and, in turn, likely result in shareholder intervention to put the Company on a path to long-awaited value creation."

15:31 EDT Norfolk Southern reaches paid sick leave agreement with BRS union - Norfolk Southern Corporation announced that it has partnered with leaders of another labor union to provide additional craft employees the ability to take up to seven days of paid sick leave per year. In total, ten of Norfolk Southern's twelve unions now have access to paid sick leave, benefitting approximately 6,900 of its dedicated railroaders. This latest agreement, reached in collaboration with the Brotherhood of Railway Signalmen, will immediately provide approximately 900 signal employees with four new days of paid sick leave per year while also offering them the flexibility to use up to three additional days of existing paid time off as sick leave. "We continue to build on the significant progress we've made with our unions to provide additional sick leave benefits to our craft railroaders," said Norfolk Southern President and CEO Alan Shaw. "Our railroaders are essential to advancing the American economy, and we are committed to listening to them and developing solutions to continuously improve their quality of life."

15:08 EDT Luminar, Volvo release Cirrus curated dataset - Luminar (LAZR) and Volvo Cars (VLVLY) released a curated dataset called Cirrus containing unique long range lidar data from Volvo Cars' test and data collection fleet. This curated dataset is being opened to industry developers and researchers in order to aid and further advance safe self-driving. Cirrus features raw data from Luminar's lidar sensors, which accurately detect objects ahead of the car out to 250 meters away. The dataset is intended to help advance research and refinement of self-driving software algorithms, in the interest of improved vehicle safety at highway speeds and in complex environments. Duke University's Pratt School of Engineering has also been contributing effort to the project. Luminar also has the capability of dynamically adjusting its scan pattern for optimized resolution up to five times standard uniform distribution. This is reflected in the dataset, which also includes uniform lidar data and corresponding camera images, and annotations for reference.

14:57 EDT Bristol-Myers' Juno get orphan designation for lisocabtagene maraleucel - Juno Therapeutics, a Bristol-Myers Squibb company, was granted FDA orphan designation for lisocabtagene maraleucel as a treatment of splenic marginal zone lymphoma, according to a post to the agency's website. Reference Link

14:40 EDT MapKure, SpringWorks, BeiGene present data from Phase 1a/1b study of BGB-3245 - MapKure, SpringWorks Therapeutics (SWTX), and BeiGene (BGNE) presented updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or refractory solid tumors harboring MAPK pathway aberrations. The ongoing Phase 1a/1b trial is an open-label, dose escalation and expansion study of BGB-3245 in adult patients with advanced or refractory solid tumors harboring MAPK pathway alterations. This portion of the study was designed to evaluate the safety, pharmacokinetics, preliminary antitumor activity of BGB-3245, and to determine its maximum tolerated dose and/or recommended Phase 2 dose to be used in select expansion cohorts. As of the data cut-off of September 1, 2022, 42 patients were treated across six dose levels. Patients were heavily pre-treated, having received a median three prior lines of therapy, including standard of care immunotherapy and targeted therapy regimens. Results demonstrated that BGB-3245 had a manageable safety profile, with adverse event findings consistent with other MAPK pathway inhibitors. The 40 mg once daily dose was determined to be the maximum tolerated dose of BGB-3245. In addition, encouraging anti-tumor activity was observed in heavily pretreated patients, with an objective response rate of 18%. The disease control rate was 79% and clinical benefit rate was 42%. Objective responders include patients with tumors harboring BRAF V600E that had progressed on prior BRAF/MEK inhibitors with or without checkpoint inhibitor treatment, BRAF Class II mutation, BRAF fusion, NRAS and KRAS mutations. Median time on treatment was approximately 5 months and 9 patients remain on treatment. These data supported the advancement of BGB-3245 into the Phase 1b dose expansion portion of the study, which has been enrolling patients since October 2022 in defined cohorts.

14:37 EDT Catalent trading resumes

14:32 EDT Catalent trading halted, volatility trading pause

14:29 EDT American Electric, Algonquin Power subsidiary terminate transaction - American Electric Power (AEP) earlier today said it "reaffirms its commitment to Kentucky customers" and outlined its strategic plans for Kentucky Power and AEP Kentucky Transco after AEP and Liberty, a subsidiary of Algonquin Power & Utilities Corp. (AQN), agreed to terminate the previously announced transaction under which AEP would sell its Kentucky operations to Liberty. "We are working diligently to reimagine our strategy with the goal of not just supporting Kentucky but being an essential part of its economic and energy future. We believe there are opportunities ahead for our Kentucky operations, and we will focus our efforts on economic development, reliability and controlling cost impacts to customers. Our team is eager to get to work implementing a refreshed long-term strategy that maximizes the full potential of our Kentucky operations - not just for AEP, but for the communities we serve. I am confident that we have the right team in place to lead this effort and power the future in Eastern Kentucky, while delivering value for customers, employees and investors," said Julie Sloat, AEP president and CEO. In the near-term, AEP plans to file a base rate case in Kentucky in June with a six-month expected commission approval process, and new rates taking effect in January 2024. In addition, AEP said it will "focus on right-sizing its rate base to better meet the region's needs and address costs while providing reliable service to customers in the near-term. This includes securitizing retired coal assets through the Kentucky commission's approval to reduce rates for customers." The company added: "AEP and its Kentucky operations leadership teams will leverage years of industry experience and expertise to take a new look at the business. AEP's refreshed Kentucky strategy represents an opportunity to move forward and be a part of Kentucky's energy future. AEP also named Cindy Wiseman as Kentucky Power president and chief operating officer. Wiseman's experience overseeing customer service, economic development and government affairs positions her well to redefine the company moving forward."

14:04 EDT Southern Company raises annual dividend by 8c per share to $2.80 - Southern Company announced it is increasing its dividend by 8c per share on an annualized basis to a rate of $2.80 per share. This marks the 75th consecutive year that Southern Company has paid a dividend on its common stock that is equal to or greater than the previous quarter. Additionally, it is the 22nd consecutive year that Southern Company has raised its dividend. "Throughout our business, we provide customers with the clean, safe, reliable and affordable energy solutions that make their lives better," said Southern Company chairman and CEO Thomas A. Fanning. "For three quarters of a century, and again today, the Southern Company board has taken action to reinforce our overall shareholder value proposition to provide regular, predictable, sustainable dividend growth supported by premier state-regulated utilities and energy infrastructure under long-term contracts."

13:57 EDT South Africa approves Microsoft's proposed takeover of Activision - The Competition Commission of South Africa held its ordinary meeting on Tuesday, 11 April 2023, to review and take decisions on matters brought before the Commission by members of the public and corporate applicants, in terms of the Competition Act as amended. The Commission has recommended that the Competition Tribunal approve the proposed transaction whereby Anchorage intends to acquire Activision (ATVI), without conditions. The primary acquiring firm is Anchorage, a company registered in accordance with the General Corporation Law of the State of Delaware. Anchorage is a wholly owned subsidiary of Microsoft (MSFT). In South Africa, Microsoft controls Microsoft Proprietary Limited and Microsoft 1968 South Africa Proprietary Limited. Anchorage does not control any firm/s in South Africa, whether directly or indirectly. Anchorage, Microsoft and all firms controlled by Microsoft are collectively referred to as the "Acquiring Group."

13:50 EDT Trine II Acquisition will not consummate initial business combination - Trine II Acquisition Corp. announced that it will redeem all of its outstanding Class A ordinary shares, effective as of May 2, because the company will not consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association. The per-share redemption price for the public shares will be approximately $10.35. There will be no redemption rights or liquidating distributions with respect to the company's warrants, which will expire worthless. The company's sponsor has waived its redemption rights with respect to the outstanding founder shares and the shares underlying the private placement warrants. After May 2, the company shall cease all operations except for those required to wind up the company's business. The company expects that NYSE will file a Form 25 with the United States Securities and Exchange Commission to delist its securities. The company thereafter expects to file a Form 15 with the Commission to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.

13:37 EDT Anixa, Cleveland Clinic present data for Phase 1 study of breast cancer vaccine - Anixa Biosciences announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine. The data presented showed that in the vaccinated women who have been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels. The presentation was made by G. Thomas Budd, M.D., of Cleveland Clinic's Taussig Cancer Institute and principal investigator of the study. This breast cancer vaccine technology was invented at Cleveland Clinic, where the trial is being conducted, and Anixa is the exclusive worldwide licensee. The trial is funded by a grant from the U.S. Department of Defense to Cleveland Clinic. The Phase 1a study is designed to evaluate the safety of the vaccine, identify the Maximum Tolerated Dose, and monitor the immune response in vaccinated women. All participants in the Phase 1a study are women who have had triple negative breast cancer within the last three years and have been curatively treated having undergone standard of care. At the time of vaccination, these participants are tumor-free, as determined by standard diagnostic techniques, but are at high risk of recurrence.

13:34 EDT Xencor presents new preclinical data from CD28 bispecific antibody platform - Xencor announced that it presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell activation was enhanced in combination with a CD3 T cell engager. The data were presented in a poster titled "Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors" (Abstract 2983) at the American Association for Cancer Research, or AACR, Annual Meeting in Orlando, Florida. "Xencor has rapidly generated multiple CD28 co-stimulatory bispecific antibodies with potential broad applicability across a range of solid tumors, and each of these programs has demonstrated compelling activity. We are leveraging the plug-and-play nature of our XmAb bispecific antibody platforms to generate and explore additional CD28 drug candidates against a broader universe of solid tumor targets," said John Desjarlais, Ph.D., executive vice president and Chief Scientific Officer at Xencor.

13:31 EDT Harpoon Therapeutics presents data for new ProTriTAC development candidates - Harpoon Therapeutics announced that it presented preclinical data on two new development candidates from the proprietary ProTriTAC platform in TROP2- and ITGB6-expressing solid tumors in poster presentations at the American Association for Cancer Research, or AACR, Annual Meeting being held April 14-19. The first candidate, TROP2 ProTriTAC, is a protease-activated T cell engager prodrug targeting TROP2. The second candidate, ITGB6 ProTriTAC, is a protease-activated T cell engager prodrug targeting integrin-beta6. "TROP2 and ITGB6 are tumor targets that are overexpressed in numerous solid tumor types and have demonstrated clinical utility when targeted as antibody drug conjugates. However, significant unmet needs remain as both the depth and the durability of response with antibody drug conjugates are typically limited. The ability to safely target TROP2 and ITGB6 with T cell engagers, as the preclinical data with our ProTriTAC platform now demonstrate, warrants further study in the clinic," said Luke Walker, M.D., Chief Medical Officer of Harpoon Therapeutics.

12:09 EDT VW presents ID.7, global electric model for upper mid-size class - Volkswagen presented the new ID.7, the brand's first global electric model for the upper mid-size class. The combination of ranges up to 700 kilometres, superior powertrain, spacious interior and premium technologies makes the ID.7 a comfortable limousine for long distance travel and opens up a new segment for the ID. family. Almost five metres long, the model also has an enhanced customer-focused operating concept and a high-quality appearance. The ID.7 launch is planned for this year in Europe and China, and from 2024 in North America. Thomas Schafer, CEO of Volkswagen Passenger Cars, said, "With the ID.7 we are taking the next step in our electric offensive. The limousine offers a high level of comfort and long ranges. Already by 2026, we will offer the widest electric range of all manufacturers in Europe - from the entry-level model for less than 25,000 euros up to the ID.7 as the new top model within the ID. family. Our goal is to achieve an electric car share of 80 per cent in Europe by 2030. As from 2033, Volkswagen will produce only electric vehicles in Europe." Reference Link

12:01 EDT M&T Bank CFO says can return capital and grow capital ratios at same time - Asked about stock buybacks going forward, M&T Bank CFO Darren King responded in part: "When we look through the quarter and what we see with the pace of risk-weighted asset growth, we see the potential actually for kind of a trifecta and that we should see a little bit of risk-weighted asset growth. As rates are rising and liquidity is constrained we think that we'll start to see some increased margin and profitability of new lending activity, which usually happens at this point in the cycle. So we'll deploy capital to those opportunities first. We will -- and we do anticipate closing the sale of the CIT business in this quarter, which will create a gain, which will help with our capital ratios, which should allow us to be in the market and repurchase some shares. And at the same time, maintain this kind of capital level that gives us a really nice cushion given the uncertainty in the market and while we wait for the SCB. Now from our perspective, if we run a little light for a quarter, it doesn't mean that the capital is gone. It just means it comes back a little bit later in the year. But we think we're in a position here which is nice where we can actually do all 3. We can grow risk-weighted assets. We can return capital and we can grow the capital ratios all at the same time."

12:00 EDT Daily S&P Biotech Bear 3x Shares falls -12.2% - Daily S&P Biotech Bear 3x Shares is down -12.2%, or -$2.32 to $16.65.

12:00 EDT Biohaven rises 8.6% - Biohaven is up 8.6%, or $1.13 to $14.22.

12:00 EDT XPeng rises 14.1% - XPeng is up 14.1%, or $1.40 to $11.31.

11:44 EDT M&T Bank up 5% as earnings call continues - Shares of M&T Bank are up $6.32, or 5%, to $122.90 as the company continues conducting its earnings conference call.

11:41 EDT Correction: M&T Bank CFO guides taxable NII to grow 20%-23% - M&T Bank CFO Darren King said during the company's Q1 earnings call, according to a transcript: "First, let's talk about net interest income outlook. The outlook for interest rates in the economy continues to change frequently. Since March 8, the 10-year U.S. government bond yield has dropped 46 basis points and the forward curve has changed meaningfully as well. We expect taxable net interest income to grow in the 20% to 23% range when compared to the $5.86B during 2022. This range reflects different rates of deposit balance growth, deposit pricing and loan growth. Consistent with the current forward curve, our forecast incorporates two 25 basis point cuts in the final quarter of this year. As we noted on the first quarter call, a key driver of net interest income in 2023 will be the ability to efficiently fund earning asset growth. We expect continued intense competition for deposits in the face of industry-wide outflows. Full year average total deposit balances are expected to be down low single digits compared to the $158.5 billion average during 2022... We expect 2023 noninterest income growth to be in the 7% to 9% range compared to the $2.23B in 2022. This outlook for noninterest income includes the impact of a bulk purchase of residential mortgage servicing rights that we completed at the end of this year's first quarter. Turning to expenses. We anticipate expenses, excluding merger-related costs, the charitable contribution and intangible amortization to be up 11% to 13% when compared to the $4.52B during 2022. Recall that approximately half of this increase reflects an extra quarter of People's United expenses. In addition, this outlook for net operating expenses includes the impact of the previously noted mortgage servicing rights purchase. We do not anticipate incurring any material merger-related costs in 2023 and and intangible amortization is expected to be in the $60M to $65M range during 2023. Turning to credit. We expect credit losses to migrate towards M&T's long-term average of 33 basis points, although the quarterly cadence could be lumpy. Provision expense over the year will follow the CECL methodology and will be affected by changes in the macroeconomic outlook as well as loan balances... Finally, turning to capital. M&T's common equity Tier 1 ratio of 10.15% at March 31, 2023, comfortably exceeds the required regulatory minimum threshold, which takes into account our stress capital buffer or SCB. We believe the current level of core capital exceeds that needed to safely run the company and to support lending in our communities. We plan to return excess capital to shareholders at a measured pace over the long term. However, in the near term, we plan to maintain a CET1 ratio slightly above the current level until the current economic uncertainty abates."

11:22 EDT Ponce Financial awarded $3.7M grant from the U.S. Treasury - Ponce Financial Group announced that the Bank has been awarded a $3.7M grant from the U.S. Treasury as part of the Community Development Financial Institutions Equitable Recovery Program which aims to help CDFI's further their mission of helping low and low-to-moderate income communities recover from the impact of Covid-19. The U.S. Treasury indicated that the grant would be disbursed in June 2023 and its utilization would be subject to eligible activities and reporting in accordance with the ERP program.

11:03 EDT Tandem Diabetes Care announces publication of meta-analysis of Control-IQ trials - Tandem Diabetes Care announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. Results demonstrate the positive clinical impact of the system's automatic correction bolusing on glucose control across a wide range of ages and demographics of people living with type 1 diabetes. People with the highest baseline blood sugar levels experienced the greatest benefit from the auto-bolus feature of the Control-IQ algorithm. Automatic correction bolusing is an automated insulin dosing feature that is only commercially available in the t:slim X2 insulin pump with Control-IQ technology. All participants were using a Dexcom G6 Continuous Glucose Monitoring System. The analysis showed an average increase in time in range of 2.8 hours and a reduction in hemoglobin A1c compared to control groups in people ages 2 to 72 years old. Improvements in time in range for subjects using Control-IQ technology were immediate, sustained, and observed across the spectrum of patient characteristics including age, race-ethnicity, parental education, family income, baseline glycated hemoglobin level, virtual vs. in-person training format, and pre-study insulin delivery method. The majority of the control group used an insulin pump, some with predictive low glucose suspend technology. Additional Data Highlights: Glycemic Control at 3 Months: Mean time in range with Control-IQ technology increased from 57 percent at baseline to 70 percent during follow-up compared to 56 percent to 57 percent in the control group, for a mean adjusted difference of 11.5 percent. Hemoglobin A1c decreased from 7.5 percent at baseline to 7.0 percent for the Control-IQ technology group, with an adjusted improvement of 0.38 percent compared to the control group. Substantial daytime and nighttime reductions in hyperglycemia and mean glucose were seen with Control-IQ technology compared with the control group. The greatest difference in mean glucose was between 4am and 8am. Time spent in hypoglycemia was low at baseline, but reductions in time less than70 mg/dL and less than54 mg/dL were still observed with Control-IQ technology compared with the control group. The rate of severe hypoglycemia events was exceedingly low and similar between Control-IQ technology and the control group. System Performance and Useability: Fewer user-initiated boluses were associated with people age 14 to 24 years and those with a baseline hemoglobin A1c of 8 percent or higher. Fifty percent or more of the total number of daily boluses for these two groups were automated. The median time the system was in active closed loop was 93 percent. Results were observed regardless of pre-study experience with an insulin pump.

11:02 EDT Eli Lilly to invest another $1.6B, add 200 jobs to Indiana production facilities - Eli Lilly and Company announced that it will invest an additional $1.6B and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the company's total commitment to $3.7B and up to 700 new jobs. The company also committed $15M over five years to the Ivy Tech Foundation to fund up to 1,000 scholarships for individuals interested in pursuing careers in pharmaceutical manufacturing.

10:59 EDT Topcon makes strategic investment in DDK Positioning, terms not disclosed - Topcon Positioning Systems has made a strategic investment in DDK Positioning Ltd, an Aberdeen-based specialist in GNSS receivers and PPP correction services. DDK Positioning delivers services exclusively over the Iridium network to provide global precision positioning services that can augment GNSS constellations to significantly enhance their accuracy for critical industrial applications. Terms of the investment are not being disclosed.

10:48 EDT SEC charges crypto trading platform Bittrex for operating unregistered exchange - The Securities and Exchange Commission charged crypto asset trading platform Bittrex, Inc. and its co-founder and former CEO William Shihara for operating an unregistered national securities exchange, broker, and clearing agency. The SEC also charged Bittrex, Inc.'s foreign affiliate, Bittrex Global GmbH, for failing to register as a national securities exchange in connection with its operation of a single shared order book along with Bittrex. The agency said, "Since at least 2014, Bittrex has held itself out as a platform that facilitated buying and selling of crypto assets that the SEC's complaint alleges were offered and sold as securities. From 2017 through 2022, Bittrex earned at least $1.3 billion in revenues from, among other things, transaction fees from investors, including U.S. investors, while servicing them as a broker, exchange, and clearing agency without registering any of these activities with the Commission. The complaint further alleges that Bittrex and Shihara, who was the company's CEO from 2014 to 2019, coordinated with issuers who sought to have their crypto asset made available for trading on Bittrex's platform to first delete from public channels certain 'problematic statements' that Shihara believed would lead a regulator, such as the SEC, to investigate the crypto asset as the offering of a security. For example, in an effort to avoid regulatory scrutiny, before Bittrex would make an asset available on its platform, Bittrex and Shihara instructed issuer-applicants to delete statements related to 'price prediction,' 'expectation of profit,' and other 'investment related terms.'" Reference Link

10:36 EDT Cadence Design extends collaboration with TSMC, Microsoft - Cadence Design Systems (CDNS) announced an expanded collaboration with TSMC (TSM) and Microsoft (MSFT), focusing on accelerating the physical verification of giga-scale digital designs. Through this latest collaboration, mutual customers can shorten design schedules and reduce compute costs by adopting the Cadence Pegasus Physical Verification System and TSMC technologies, leveraging the ready-to-use Cadence CloudBurst Platform and Microsoft Azure cloud.

10:26 EDT Hershey to acquire two manufacturing plants from Weaver Popcorn Manufacturing - The Hershey Company has entered into a definitive agreement to acquire two manufacturing plants from Weaver Popcorn Manufacturing, a leader in popcorn production and co-packing, and a co-manufacturer of Hershey's SkinnyPop brand. Through the deal, Hershey will acquire Weaver's operations in Bethlehem, Pennsylvania and Whitestown, Indiana. The acquisition is designed to enable the company to sustain strong growth for its SkinnyPop brand by strengthening internal supply chain capabilities in combination with its network of strategic suppliers and co-manufacturers. The acquisition is subject to customary regulatory approvals and will be financed with cash on hand, as well as short-term borrowings.

10:22 EDT Merus announces interim clinical data on petosemtamab in HNSCC - Merus announced interim clinical data as of a February 1, 2023 data cutoff, from the ongoing phase 1/2 trial of the bispecific antibody petosemtamab in previously treated head and neck squamous cell carcinoma. The Plenary Session presentation by Dr. Ezra EW Cohen, Moores Cancer Center, UC San Diego Health, will occur today at the American Association of Cancer Research Annual Meeting 2023, taking place in Orlando, Florida. Petosemtamab, or MCLA-158, is a human IgG1 Biclonics designed to bind to cancer cells expressing epidermal growth factor receptor and leucine-rich repeat-containing G protein-coupled receptor 5. Updated information and observations from plenary presentation of the ongoing phase 1/2 trial include: As of the February 1, 2023 data cutoff date, 49 previously treated HNSCC patients were treated with petosemtamab at the recommended phase 2 dose of 1500 mg intravenous every two weeks: Patient population: Median age was 63; 78% were male; Median prior lines of systemic therapy was 2; including PD-(L)1 inhibitor in 96% of pts, chemotherapy in 94% and platinum-based chemotherapy in 92% of pts; 2 pts received prior cetuximab; Most frequent primary tumor locations were oropharynx, oral cavity, and larynx; 43 pts were evaluable for efficacy, receiving greater than or equal to2 treatment cycles with greater than or equal to1 post-baseline tumor assessment or experiencing early progressive disease: Antitumor activity among 43 pts: Overall responses rate was 37.2% by RECIST 1.1. per investigator assessment, including 15 confirmed partial responses and 1 confirmed complete response; Disease control rate was 72.1%; Median time to response was 1.8 months; Median duration of response was 6.0 months, with 10 of 16 responders ongoing, and 12 of 43 patients overall ongoing at the time of the data cutoff; Median progression free survival was 5.3 months; with 29 of 43 pts progressing and 14 of 43 pts censored; Median overall survival was 11.5 months; with 29 of 49 pts still alive at the data cutoff date; Petosemtamab continued to demonstrate a manageable safety profile: 80 pts were treated with 1500 mg petosemtamab every two weeks across dose escalation and expansion cohorts of the study; Gastrointestinal and skin toxicities were mostly mild to moderate; No treatment-related Grade 5 AEs: Most frequent related AEs were signs and symptoms of infusion-related reactions; 74% Grade 1-4, 21% Grade 3-4; Mainly occurred during first infusion; 6 of 80 pts discontinued on Day 1 due to a Grade 3-4 IRR; For all patients rechallenged after an IRR, rechallenge was successful; IRRs were manageable with prophylaxis/ prolonged infusion.

10:18 EDT Allogene Therapeutics presents interim Phase 1 data on ALLO-316 - Allogene Therapeutics presented interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company's first AlloCAR T investigational product candidate for solid tumors, in an oral presentation at the American Association for Cancer Research Annual Meeting in Orlando, Florida. The presentation follows the release of initial ALLO-316 data reported at the Company's R&D Showcase event in November 2022. The ongoing Phase 1 TRAVERSE study is enrolling patients with advanced or metastatic renal cell carcinoma who have progressed on standard therapies that include an immune checkpoint inhibitor and a VEGF-targeting therapy. Emerging data from this trial have demonstrated the potential of an AlloCAR T to treat CD70 expressing RCC. In this trial, ALLO-316 showed early anti-tumor activity with deepening responses over time. As of the March 23, 2023 data cutoff, 19 patients were enrolled in the Phase 1 trial, 10 of whom had RCC confirmed to express CD70. The median time from enrollment to the start of therapy was five days. In the ongoing dose escalation phase of the TRAVERSE trial, patients will receive lymphodepletion followed by ALLO-316 at one of four cell dose levels. The data reported to date is primarily from the DL1 and DL2 cohorts. Anti-tumor activity was primarily observed in patients with tumors confirmed to express CD70. Among 18 patients evaluable for efficacy, the disease control rate was 89%. In the 10 patients whose tumors were known to express CD70, the disease control rate was 100%, which included three patients who achieved partial remission. The longest response lasted until month eight. There was a trend toward greater tumor shrinkage in patients with higher levels of CD70 expression. There were 19 patients evaluable for safety. To date, ALLO-316 has demonstrated an adverse event profile generally consistent with autologous CAR T therapies. One dose-limiting toxicity of Grade 3 autoimmune hepatitis occurred in the second dose level. Cytokine release syndrome was all low-grade with the exception of one Grade 3. Neurotoxicity, which is now defined more broadly, was generally low grade and reversible with most events being fatigue or headache. There were no cases of immune effector cell-associated neurotoxicity syndrome. Infections occurred in eight patients of which four were Grade 3+ including one Grade 5 respiratory failure due to Covid-19 infection deemed unrelated to study treatment. Grade 3+ prolonged cytopenia was observed in three patients. There were no cases of graft-versus-host disease. The Dagger technology, which is a feature of ALLO-316, is designed to resist rejection of AlloCAR T cells by the host immune cells, thereby supporting expansion and enabling a prolonged window of persistence during which AlloCAR T cells can target and destroy cancer cells. Initial translational data from the TRAVERSE trial demonstrates the suppression of host T cells and marked peak expansion of ALLO-316 despite the relatively low cell doses tested. In addition to ALLO-316, the Company plans to deploy Dagger technology to potentially enhance the persistence and activity of next generation AlloCAR T products.

10:12 EDT Rogers Communications repatriates hundreds of Shaw jobs back to Canada - Rogers Communications announced it is repatriating hundreds of Shaw jobs back to Canada as part of its commitment to a 100% Canadian-based customer service team. The jobs, currently based outside of Canada, will be located in British Columbia, Alberta and Manitoba to ensure every phone call or online chat with customers of the combined company is answered by a customer solution specialist based in Canada. Rogers' merger with Shaw was completed on April 3, 2023, and the repatriation of jobs to Canada has already started, with customer care roles to be in place by Canada Day and all jobs fully transitioned by Q3 2023. In addition to bringing hundreds of jobs back to Canada, Rogers plans to hire 1,000 customer service representatives across the country. Rogers is also committed, as part of the merger with Shaw, to invest $6.5 billion over the next five years to bring fast, reliable networks to more communities across Western Canada. This includes expanding and improving 5G coverage along rural highways and in over 300 communities. These investments are expected to add over $7 billion in GDP to the region and create thousands of jobs over the next five years.

10:08 EDT Black Knight, Restb.ai form strategic alliance for product suite integration - Restb.ai announced a strategic alliance with Black Knight to integrate the Restb.ai MLS Product Suite seamlessly into the Black Knight Paragon MLS platform and offer the integrated products to Black Knight's customers .

10:00 EDT Manchester United falls -10.4% - Manchester United is down -10.4%, or -$2.28 to $19.74.

10:00 EDT State Street falls -14.0% - State Street is down -14.0%, or -$11.23 to $68.80.

10:00 EDT BigBear.ai rises 10.0% - BigBear.ai is up 10.0%, or 32c to $3.53.

09:58 EDT Charles Schwab pauses buyback program amid 'regulatory uncertainty' - Charles Schwab said earlier in its earnings release, "Maintaining the capital and liquidity required to support Schwab's long-term growth remains our primary balance sheet objective. We increased our quarterly common dividend by 14% to $.25 per share and returned capital via common and preferred stock repurchases. Even with the accelerated capital return during the first two months of the quarter, our Tier 1 Leverage Ratio finished at 7.1%. In light of recent events within the U.S. banking sector, and the resulting regulatory uncertainty, we have decided to pause our active buyback program. That being said, opportunistic capital return is still an important component of our 'through the cycle' financial formula. Ultimately, we believe the current headwinds will prove transitory and we remain well positioned to deliver long-term value to our stockholders."

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -8.7% - ProShares UltraShort Bloomberg Natural Gas is down -8.7%, or -$6.31 to $66.59.

09:47 EDT State Street falls -14.7% - State Street is down -14.7%, or -$11.74 to $68.29.

09:47 EDT Peabody Energy rises 8.8% - Peabody Energy is up 8.8%, or $2.21 to $27.44.

09:39 EDT State Street sees Q2 servicing fees up 1%-2% q/q - Sees Q2 management fees flat to up 1% q/q.

09:34 EDT Vinco Ventures chairman urges shareholders to vote for company proposals - Rod Vanderbilt, Executive Chairman of the Board of Directors issued a letter to shareholders outlining the Company's strategy and providing business execution updates in advance of the 2023 Annual Meeting of Stockholders. The letter read, in part, " Despite the challenges that Vinco has experienced over the past year, our team has been diligently developing and executing on a clear strategy to build a solid foundation for growth and shareholder value creation. With our Annual Meeting coming up on April 27, 2023, I wanted to provide some important updates and background on the business and our strategy. I also want to explain why it is critical that you vote FOR all the Company's proposals at the Annual Meeting to allow us to pursue the strategy we have laid out to drive growth and enhance the value of your investment. We have a high-quality leadership team and Board in place and are excited to execute on our business strategy. Importantly, we have made substantial progress in removing legacy roadblocks in terms of financial reporting. I am happy to report that we have filed our Quarterly Report on Form 10-Q for the quarter ending September 30, 2022 with the Securities and Exchange Commission ("SEC") on April 10, 2023, reflecting the culmination of months of hard work by our financial team and auditors. The Company is also working expeditiously to complete its 2022 Audit and file its Annual Report on Form 10-K for the year ended December 31, 2022, as soon as possible but not later than June 2, 2023. I am also happy to report that on April 14, 2023, we received a letter from the Nasdaq stating that The Nasdaq Hearings Panel granted our request to continue our listing on The Nasdaq Stock Market. I am also pleased to share that we plan to announce the appointment of a permanent Chief Executive Officer and Chief Financial Officer soon. Please stay tuned for further updates...The estimated annualized revenues from the a360 acquisition, when combined with existing assets of the Company, will be provided for 2023 after we file the 2022 annual report. We intend to keep you updated on potential changes to our guidance as we continue to pursue our strategy of acquiring EBITDA-positive companies. Discussions are ongoing with multiple potential counterparties and we anticipate announcing additional definitive acquisition agreements in the coming months. Executing against our multi-pillar M&A growth strategy will likely affect our estimated annualized revenue and operating income guidance. Your approval of the proposals up for consideration at the Annual Meeting is critical to enable Vinco to successfully execute on our growth and value creation strategy. Approving the a360 acquisition - including the purchase of the National Enquirer - is an essential first step. Further, approving the increase in authorized shares and reverse stock split will give the Company necessary financial flexibility to operate successfully and also address potential NASDAQ-delisting concerns. We also strongly recommend shareholders vote FOR the reelection of our five Board members, who collectively possess the right industry experience and skillsets to oversee the successful execution of the Company's strategy to unlock value for shareholders."

09:29 EDT Mace Security enters distribution agreement with SurgePays - Mace Security International (MACE) has entered into a distribution agreement with SurgePays (SURG). The agreement provides for the distribution of pepper spray and other personal defense products through the SurgePays network of thousands of corner stores, bodegas and gas stations.

09:27 EDT State Street sees Q2 NIII down 5%-10% sequentially

09:26 EDT State Street sees fee revenue up 4%-5% in Q2

09:19 EDT Allarity doses first patient in Phase 1b trial of stenoparib with dovitinib - Allarity Therapeutics dosed its first patient in Phase 1b of its clinical trial for the novel combination therapy of two drugs, stenoparib and dovitinib. The company is evaluating the safety, dosing, and potential therapeutic benefit of this combination therapy on advanced solid tumors, including ovarian cancer. Both stenoparib and dovitinib have shown promising results for cancer treatment in the past. Stenoparib is a poly-ADP ribose polymerase inhibitor, which blocks the repair of single-stranded DNA within cancerous cells. Dovitinib is a pan-tyrosine kinase inhibitor with an anti-angiogenic activity that cuts off the blood supply to the cancerous region, resulting in an increase in tumor DNA damage, the repair of which can then be blocked by Stenoparib. Now, Allarity Therapeutics is exploring the potential for a combination therapy that uses these two drugs to tackle solid tumors.

09:18 EDT Cogent Biosciences presents nonclinical data at AACR - Cogent Biosciences announced updated preclinical data from the Company's pipeline programs, including its novel EGFR-sparing brain-penetrant ErbB2 inhibitor and its next-generation selective fibroblast growth factor receptor 2 program. The data are being presented in poster sessions at the American Association for Cancer Research, AACR, 2023 Annual Meeting. Cogent also announced the initiation of Part 2 of the Company's ongoing APEX trial with bezuclastinib in Advanced Systemic Mastocytosis. "We are pleased to share our progress highlighting the Cogent Research Team in their ongoing effort to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet medical need," said Andrew Robbins, Cogent's President and Chief Executive Officer. "Separately, based on bezuclastinib's impressive and consistent clinical activity, safety and tolerability, we are also excited to announce the initiation of Part 2 of the APEX trial in AdvSM at a once-daily dose of 150 mg. We remain on track to provide clinical updates in the second half of 2023 from both APEX and SUMMIT, our trial of bezuclastinib in NonAdvSM patients, as well as updated clinical results from the PEAK lead-in trial in GIST patients this quarter."

09:17 EDT iKena Oncology shares differentiation profile of IK-930 - Ikena Oncology announced that it will present preclinical data in two poster presentations highlighting the Company's novel Hippo pathway inhibitor, IK-930, at the American Association for Cancer Research, AACR, Annual Meeting taking place in Orlando, FL from April 14-19, 2023. Data being shared today reveals that IK-930 selectively binds and inhibits TEAD1 and further describes the mechanism for its antitumor activity. Key advantages demonstrated in the nonclinical studies include IK-930's superior tolerability and comparable antitumor activity compared to panTEAD inhibition, resulting in a significantly improved projected therapeutic window in cancer patients. IK-930 was designed as a TEAD1-selective inhibitor to avoid on-target renal toxicity expected from panTEAD inhibition. TEAD1 is the most highly expressed TEAD paralog in mesothelioma and epithelioid hemangioendothelioma. The data being presented support the ongoing IK-930 Phase 1 program in patients with Hippo mutated cancers and the planned expansion into combinations of IK-930 with other targeted therapies in multiple cancer types, including across EGFR and RAS mutated cancers, to potentially delay or even reverse therapeutic resistance.

09:15 EDT Avalon announces commercial launch of KetoAir Breathalyzer - Avalon GloboCare announced the commercial launch of the KetoAir breathalyzer device and related accessories at the KetoCon Austin 2023 conference, which is being held on April 21-23, 2023 in Austin, Texas. Avalon will showcase the KetoAir in booth #523. KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence nutritionist consultation for ketogenic dietary management.

09:14 EDT Vaccitech presents interim data from Phase 1b/2 study of VTP-200 - Vaccitech will present topline data from the APOLLO clinical trial at the 35th Annual International Papillomavirus Conference, IPVC. The APOLLO trial is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus, HPV, infection. The data will be presented as a poster at IPVC in Washington, D.C. on Thursday, April 20, 2023 at 2 PM EDT, by Dr. Meg Marshall, Chief Medical Officer of Vaccitech. "The safety and immunogenicity data presented at IPVC shows the potential of VTP-200 in treating persistent high-risk HPV infections. Currently, women with persistent HPV infections have no treatment options until they develop high grade lesions," said Meg Marshall, CMO of Vaccitech. "We believe VTP-200 has the potential to address a serious unmet need and look forward to sharing the results of the final analysis, to include data on clearance of infection and cervical lesions, in 2024."

09:10 EDT XBiotech announces first subject enrollment in Phase I trial for Hutrukin - XBiotech has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Emergency use of "clot-busting" drugs or mechanical catheters to re-open arteries after a stroke is associated with a phenomenon known as reperfusion injury. Reperfusion injury is where the return of blood supply after removing the clot from the artery results in increased brain injury or death. Hutrukin therapy is intended to be provided immediately prior to the clot-busting procedure, where the drug may reduce inflammatory injury associated with reperfusion. There is currently no drug known to be effective to reduce reperfusion injury. Hutrukin could, therefore, potentially represent a significant advance in the management of stroke patients. The current Phase I study will evaluate three dose levels of Hutrukin for safety and will measure the corresponding blood levels of Hutrukin with increasing doses. Findings will guide dosing and safety expectations for the next phase of studies.

09:08 EDT Tempest announces new translational, preclinical data presented at 2023 AACR - Tempest Therapeutics announced that new data from its TPST-1120 and TREX1 programs were highlighted in two poster presentations at the 2023 American Association for Cancer Research, AACR, Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentation for TPST-1120, a clinical-stage oral selective PPAR antagonist, highlighted new translational biomarker findings from the completed monotherapy and nivolumab combination therapy dose escalation Phase 1 trial showing on-target changes in gene signatures in the peripheral blood that were dependent upon drug exposure levels. The presentation for Tempest's preclinical TREX1 inhibitor program, designed for tumor-selective activation of the STING pathway, is the first public demonstration of human TREX1 enzyme-TREX1 inhibitor X-ray co-crystal structures, which has facilitated the development of potent and specific TREX1 inhibitors with drug-like properties. "We are very excited to report these significant advances in the TPST-1120 and TREX1 programs," said Tom Dubensky, Ph.D., president of Tempest. "We look forward to the further clinical development of TPST-1120, potentially in multiple oncology indications, and are working to develop a TREX1 inhibitor to begin human clinical trials with this differentiated approach designed to selectively activate the STING pathway broadly in advanced metastatic disease."

09:07 EDT Zentalis announces preclinical data on Cyclin E1 at AACR annual meeting 2023 - ZentalisTM Pharmaceuticals announces preclinical data that supports CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib, the Company's potentially first-in-class Wee1 inhibitor product candidate. These new preclinical data demonstrate that azenosertib drives cancer cell death in Cyclin E1-high tumor cells in vitro and substantially inhibits the growth of Cyclin E1-high, patient-derived, in vivo tumor models. The findings are being presented today at the 2023 American Association for Cancer Research Annual Meeting, in a poster entitled "Cyclin E1 protein overexpression sensitizes ovarian cancer cells to azenosertib, a novel, selective and orally bioavailable inhibitor of Wee." The study analyzed data from a panel of patient-derived ovarian cancer cell lines in vitro and in vivo models of ovarian cancer. The results show that high Cyclin E1 protein expression is significantly associated with sensitivity to azenosertib, and that artificial overexpression of Cyclin E1 in cell lines with low endogenous Cyclin E1 expression sensitizes those cells to azenosertib. The study also provides supportive data for several relevant standard of care chemotherapy combinations based on in vitro synergy assays and suggests that Cyclin E1 expression is a relevant clinical predictive marker. The Company now anticipates sharing these clinical data in the first half of 2023, in advance of original guidance. Another poster being presented at AACR by the Ivy Brain Tumor Center at Barrow Neurological Institute entitled "Tumor Pharmacokinetics, Pharmacodynamics and Efficacy Analysis of Wee1 inhibitor, Azenosertib in Patient-Derived Xenograft Models of Glioblastoma," demonstrates that azenosertib can achieve pharmacologically-relevant intracerebral free-drug concentrations, and that pharmacodynamic activity is observed in a preclinical glioblastoma model.

09:06 EDT FSD Pharma doses sentinel subjects in FIH trial of Lucid-MS for MS treatment - FSD Pharma announced completion of the first-in-human FIH sentinel dosing of Lucid-21-302 or Lucid-MS in the Company's Phase I clinical trial evaluating its novel drug candidate as an orally-administered treatment for Multiple Sclerosis . The sentinel dose was completed on Sunday, April 16, 2023. "Dosing the sentinel subject is a major achievement for our team and culmination of more than a decade of very promising research by a seasoned development team passionate about changing the future treatment paradigm for patients dealing with the debilitating effects of MS," said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma. "Current MS treatments are immunomodulatory and include repeated subcutaneous or intramuscular injections for treating the symptoms of MS. We envision a day where an oral medication will protect or even help repair myelin in the central nervous system, a hallmark feature of the disease. We are optimistic Lucid-MS has this type of paradigm-shifting potential and the sentinel dosing is a critical step in advancing this pipeline forward."

09:06 EDT IN8bio announces preclinical data for CAR Platform, launches CD33 Program - IN8bio announced preclinical data for its novel non-signaling CAR platform and the launch of its INB-330 program in AML. The new data included preliminary results for the nsCAR platform targeting CD33, a challenging but potentially impactful target in AML. The data were presented in a poster session at the American Association for Cancer Research Annual Meeting 2023. IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue. By using a CAR that lacks a signaling domain, IN8bio believes it has created a technology that enables these cells to differentiate between tumor and healthy tissue, even when both express the CAR-targeted antigen. The power of the nsCAR technology to selectively target tumor cells was shown in proof-of-concept studies against the validated target of CD19. Preliminary data showed a gamma-delta CD19 nsCAR killed 80% of leukemia cells versus only 5% of healthy B cells, which both express the CD19 target. The new data presented at AACR includes early preclinical results for the INB-330 program targeting CD33 for AML, an important but challenging target due to its expression on both leukemic cells and hematopoietic stem cells. Previous therapies targeting CD33 were limited due to the significant side effects resulting from the unintended targeting of these HSCs. The data presented at AACR showed that a CD33 targeting nsCAR construct was successfully engineered into gamma-delta T cells. The ns33CAR cells were able to distinguish between leukemic cells and healthy monocytes isolated from peripheral blood, both of which express CD33. The ns33CAR demonstrated anti-leukemic activity against AML, B-cell acute lymphoblastic leukemia, and chronic myeloid leukemia cell lines. These preliminary findings support the ongoing evaluation of INB-330 in AML and improvements in transduction and CAR optimization are ongoing.

09:05 EDT State Street CEO: Operating environment in Q1 'eventful' - Comments taken from Q1 earnings conference call.

09:04 EDT AffaMed Therapeutics approved for Phase 3 trial in China for DEXTENZA - AffaMed Therapeutics announced that China's National Medical Products Administration has approved AffaMed's Clinical Trial Application to initiate a Phase 3 registrational study in China to investigate the efficacy and safety of DEXTENZA in subjects following ophthalmic surgery. In addition, AffaMed is pleased to announce that DEXTENZA has recently been approved in Macau, China for the treatment of ocular itching associated with allergic conjunctivitis. In October 2020, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets. DEXTENZA is approved in the U.S. and Macau for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis. Following this CTA approval, AffaMed will soon initiate the proposed registrational study in China.

09:02 EDT Precision Optics appoints Mahesh Lawande as COO - Precision Optics appointed medical device and aerospace/defense industry manufacturing veteran, Mahesh Lawande, as COO effective April 24. From 1995 through 2019, Lawande held various operations and engineering roles with Siemens and Draeger, most recently as Senior Director of Supply Chain Operations in North America for Draeger Medical Systems, a multi-billion-dollar medical device and industrial safety company. Recently, Lawande was Director of Operations for the Peabody, MA headquarters site at Analogic Corporation.

09:01 EDT State Street still sees buying back up to $4.5B this year - State Street said it continues to expect FY23 total common share buyback of up to $4.5B to be repurchased at pace over the course of the year, subject to market conditions. Comments taken from Q1 earnings conference call presentation slides.

08:56 EDT Targa Resources appoints Joel Thomas as SVP, finance, treasurer - Targa Resources announce that Joel Thomas has been appointed Senior Vice President - Finance and Treasurer of the Company effective April 13, 2023. Joel joined Targa in 2012 where he served as Associate of Corporate Development and after increasing responsibilities through his time at Targa, was most recently Vice President of Corporate and Commercial Development.

08:55 EDT Innoviva trading halted, news pending

08:50 EDT Sabine Royalty Trust announces 69.95c cash distribution payable on April 28 - Argent Trust Company, as Trustee of the Sabine Royalty Trust declared a cash distribution to the holders of its units of beneficial interest of 69.95c per unit, payable on April 28, to unit holders of record on April 17 This distribution reflects primarily the oil production for January 2023 and the gas production for December 2022. Preliminary production volumes are approximately 68,608 barrels of oil and 1,259,109 Mcf of gas. Preliminary prices are approximately $80.65 per barrel of oil and $4.71 per Mcf of gas.This month's distribution is higher than the previous month's primarily due to increased production due to the timing of receipts through the end of the month as compared to the previous month's timing of receipts, including an increase in oil pricing. The production from all the new horizontal gas wells in Panola County, Texas, has contributed approximately $1,642,812 reflecting December production including the recent new wells. All volumes and pricing are included in the tables below. Additionally, for the other three horizontal wells, also in Panola County, there were two months receipts totaling $544,000 posted for this month's distribution. As more regular monthly receipts are made in the months to come, additional information will be made available.

08:48 EDT Cincinnati Financial reports preliminary Q1 storm losses of $235M - Cincinnati Financial's consolidated Q1 results are expected to include pretax catastrophe losses of approximately $235M - representing an impact on the Q1 combined ratio of approximately 12.8 percentage points, based on estimated property casualty earned premiums. The company's 5-year historical average contribution of catastrophe losses to the combined ratio is 6.3 percentage points for Q1. The catastrophe loss estimate includes $171M in aggregate for three March storms that produced tornadoes in several states, in addition to less severe storms. The estimate for total Q1 catastrophe losses incurred includes approximately $110M for the commercial lines insurance segment; $115M for the personal lines insurance segment; $1M for the excess and surplus lines insurance segment; $3M for Cincinnati Re and $6M for Cincinnati Global Underwriting. Estimated losses and expenses from catastrophe-related claims are expected to bring the company's Q1 property casualty combined ratio to approximately 99% to 103%. Net written premium growth is estimated to be approximately 6% for the quarter.

08:46 EDT Porsche Cars Canada reports Q1 sales of 2,211 units - Porsche Cars Canada reported first-quarter total sales of 2,211 units, besting any previous results for a January to March period. This represents a year-over-year increase of 4%. Porsche Approved Certified Pre-Owned vehicle sales also achieved a stellar first quarter with 788 units reported, an increase of 16% versus the same period in 2022. "We are delighted to report our best first-quarter Canadian sales results in this milestone year for the brand," said John Cappella, President & CEO, Porsche Cars Canada, Ltd. "75 years on, our brand continues to bring excitement and fascination with every Porsche sports car delivery."

08:42 EDT Veracyte: Decipher Prostate Genomic Classifier may aid prostate cancer treatment - Veracyte announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease and who may therefore benefit from systemic treatment intensification. The data show that, in men with high-risk and very high-risk disease, Decipher Prostate scores are highly correlated with upstaging predictions made by a clinical algorithm shown to predict prostate-specific membrane antigen positron emission tomography positivity. "Prostate cancer patients with clinically high-risk and very high-risk disease are prone to treatment failure due to micrometastatic disease that was not detected at the time of initial presentation, so it is imperative that we have tools to accurately identify these patients and intensify their treatment accordingly," said Amar U. Kishan, vice chair of Clinical and Translational Research and chief of the Genitourinary Oncology Service, UCLA Jonsson Comprehensive Cancer Center, and an investigator for the study. "Our findings suggest that a high Decipher Prostate score is highly correlated with the risk of having disease outside the prostate identified on advanced molecular imaging. These patients are likely to benefit from upfront systemic treatment intensification. Ongoing clinical trials are designed to prove this."

08:41 EDT Siyata Mobile partners with Entropia for European rollout of SD7 - Siyata Mobile announces Entropia Investments, a provider of secure mobile mission-critical communications services to a wide range of end-users in the Netherlands, northern Belgium and the United Kingdom, is to commence selling Siyata's mission-critical PoC SD7 solution in the second quarter 2023.

08:39 EDT Itafos provides overview on phosphare market, key value drivers - Itafos announced that it has posted a corporate presentation on the Company's website, containing an overview of the phosphate market and key value drivers for Itafos including: Mega-trends driving long-term phosphate demand; Current industry capacity additions insufficient to meet global growth; Scaled and highly cash-generative North American phosphate operations at Conda; Strategic location West of the Mississippi; Husky 1 / North Dry Ridge mine life extension and development underway with preliminary mineral resource mine life to 2037; potential for additional mineral resources through leases and third-party agreements; Current scarcity of global phosphate mineral resources expected to drive attractive potential upside from Itafos' portfolio of overseas assets; Proven management team with a history of delivering value for stakeholders. David Delaney, CEO, commented: "The Company is well positioned to capitalize on a number of global mega-trends. Itafos' portfolio of attractive assets, supplemented by the mine life extension project at Conda which remains on track, strongly positions the Company for the future."

08:37 EDT Miovision raises $260M in growth funding - Miovision has raised $260M in growth funding in a round co-led by TELUS Ventures, Maverix Private Equity and Export Development Canada.

08:36 EDT Corbus Pharmaceuticals' CRB-601 shows anti-tumor activity - Corbus Pharmaceuticals announced details of new pre-clinical data on CRB-601, its avbeta8 blocking antibody, presented at the 2023 American Association for Cancer Research annual meeting April 14-19 in Orlando. The poster explores the relationship between CRB-601 antitumor activity, PK and its binding to the alphavbeta8 receptor in the tumor. In addition, the impact on TGFbeta pathway signaling and tumor immune cell population are also presented. CRB-601 exhibited dose dependent tumor growth inhibition in the EMT6 tumor model which was significantly augmented in combination with anti-PD1 therapy. These effects were associated with changes in tumor micro-environment immune cell populations with marked increases in infiltrating T cells, NK cells and M1 polarized macrophages. Efficacy correlated with cell surface alphavbeta8 occupancy by CRB-601. CRB-601 treatment downregulated phosphorylation of SMAD proteins pSMAD2 and pSMAD3, consistent with blockade of the canonical TGFbeta signaling pathway.

08:36 EDT Mobiquity Technologies adds products to ATOS 2.0 platform - Mobiquity Technologies announces the addition of new products to its new ATOS 2.0 platform. The enhanced platform harnesses artificial intelligence and bid-based learning models to optimize ad bidding and targeting, providing a cutting-edge solution for advertisers navigating the challenges of a privacy-centric world where first-party data is becoming a scarce resource. By using bid-based learning models, Mobiquity Technologies' AI engine continually trains itself on real-time bidding data, allowing it to predict and optimize ad placements with remarkable accuracy. This innovative approach to ad bidding not only maximizes ROI for advertisers but also minimizes reliance on third-party data, ensuring compliance with stringent privacy regulations.

08:35 EDT Roblox reports March revenue $212M-$223M - Roblox released certain key metrics for the month of March. Daily active users, or DAUs, were 66.2M, up 26% year-over-year. Hours engaged were 4.8B, up 26% year-over-year. Estimated revenue was between $212M and $223M, up 15%-21% year-over-year. Estimated bookings were between $247M and $255M, up 23%-27% year-over-year. Estimated average bookings per daily active user were between $3.73 and $3.85, which represents a year-over-year change of down 2% to up 1%.

08:34 EDT Color Star Technology unit enters strategic cooperation with TL Boxing Promotion - Color Star Technology announces that its subsidiary, Color Metaverse Pte. Ltd., has officially begun a strategic cooperation with TL Boxing Promotion. Color Star's software, ColorWorld Metaverse, will begin to introduce boxing content, and create a tailor-made metaverse headquarters for TL, and both parties will work together to organize and promote boxing-related events and activities.

08:33 EDT Lipella Pharmaceuticals enters collaboration agreement with Cook MyoSite - Lipella Pharmaceuticals has entered into a manufacturing collaboration agreement with Cook MyoSite to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10, aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA. Lipella recently released positive topline results from its Phase 2a clinical trial evaluating LP-10 as a drug candidate for hemorrhagic cystitis, a rare and debilitating disease with no FDA approved treatments currently available. The collaboration with Cook MyoSite, a company with 19 years of Good Manufacturing Practice manufacturing expertise, is expected to greatly accelerate Lipella's ability to bring new treatments to patients with unmet needs.

08:31 EDT National Energy Services secures multiple contract extensions totaling $100M - National Energy Services Reunited Corp. announced that its subsidiary, Gulf Energy, successfully completed negotiations with multiple clients in Oman to extend existing Well Intervention contracts for up to five years.

08:29 EDT Mobile Global Esports receives non-compliance notice from Nasdaq - Mobile Global Esports has received a notification letter from the NASDAQ Stock Market LLC dated April 11, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ. This press release is issued pursuant to NASDAQ Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 31 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 31 consecutive business days from February 24, 2023 to April 10, 2023, the Company did not meet the minimum bid price requirement. In accordance with the NASDAQ Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until October 9, 2023, to regain compliance with NASDAQ Listing Rule 5550(a)(2). To regain compliance, the Company's ordinary shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days. In the event that the Company does not regain compliance by October 9, 2023, the Company may be eligible for additional time to regain compliance or may face delisting. The receipt of the Notification Letter has no immediate effect on the listing of the Company's common shares, which will continue to trade uninterrupted on NASDAQ under the ticker "MGAM." The Company intends to drive shareholder value through expansion of operations and offerings in the Indian esports market while continuing to vigilantly manage its resources to address the minimum share bid price requirement in due course.

08:29 EDT Ra Medical Electrophysiology Division participating in EHRA Conference - Ra Medical Systems announced that its wholly owned subsidiary, Catheter Precision, Inc., participates in the European Heart Rhythm Association. EHRA will take place in Barcelona, Spain from April 16-18. As a branch of the European Society of Cardiology, the European Heart Rhythm Association is the leading network of European Cardiac Rhythm Management. The EHRA is a strong association with more than 4,100 members around the globe, including physicians, arrhythmologists, young electrophysiologists, nurses and allied professionals. David Jenkins, CEO of Ra Medical Systems, said, "The acceptance of clinical science provides an opportunity for the EP community to come together and discuss ways to improve treatment of cardiac arrhythmias. Multiple abstracts from leading physicians is indicative of the important roll VIVO has in aiding ventricular ablations and signals clinical acceptance and adoption of VIVO among the community."

08:27 EDT Porch Group announces $333M convertible notes financing - Porch Group announced the pricing of a private offering of $333 million aggregate principal amount of its 6.75% Senior Secured Convertible Notes due 2028 in a private placement transaction, and a concurrent privately negotiated repurchase of $200 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2026. The New Notes offering and Existing Notes repurchase are expected to close concurrently on April 20, 2023, subject to customary closing conditions. The New Notes will be convertible into cash, shares of common stock of the Company, or a combination of cash and shares of common stock at Porch's election at an initial conversion rate of 39.9956 shares of common stock per $1,000 principal amount of the New Notes, which is equivalent to an initial conversion price of approximately $25.00 per share. Porch intends to use the net proceeds from the New Notes offering to repurchase $200 million of the Existing Notes and to fund the repayment of a $10 million senior secured term loan of a Porch Group subsidiary, in each case plus accrued and unpaid interest thereon and related fees and expenses, and use the remainder of the net proceeds for general corporate purposes. Following the closing of this transaction, Porch Group will hold: $225 million aggregate principal amount of the unsecured Existing Notes due 2026; $333 million aggregate principal amount of secured New Notes due 2028. The transaction is additionally expected to result in approximately $100 million of additional cash to Porch Group, net of the debt repayments described above and payment of related fees and expenses.

08:23 EDT AbbVie announces provincial reimbursement for VRAYLAR - AbbVie announced that VRAYLAR is now listed as an exception medication status on the list of medications of the Regie de l'assurance maladie du Quebec for the treatment of schizophrenia. This announcement comes 12 months after the approval of VRAYLAR by Health Canada, bringing a new treatment option to Canadians living with schizophrenia.

08:20 EDT Windtree announces issuance of new dual mechanism SERCA2a activator patent - Windtree Therapeutics announced that the European Patent Office has granted Patent No. 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates. Windtree has preclinical drug candidates with dual mechanisms of action as well as pure SERCA2a activators. The new patent, titled: "17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE," provides patent protection until July 2038 for the family of compounds with a dual mechanism of action. "SERCA2a activity is decreased in heart failure. Windtree believes therapies that activate SERCA2a represent a potential important advancement in heart failure treatment for patients," said Craig Fraser, CEO and President of Windtree Therapeutics. "The development strategy with these dual mechanism compounds is for potential 'fast follow-on' drug candidates that can leverage the experience with istaroxime and provide the potential added feature of oral bioavailability for use as a treatment for chronic heart failure. Compounds that activate SERCA2a have been aggressively pursued as much sought-after targets in the treatment of heart failure, and Windtree has found a unique mechanism that activates SERCA2a."

08:19 EDT Innovation Pharmaceuticals Brilacidin antifungal research published - Innovation Pharmaceuticals announced publication of Brilacidin antifungal research in Nature Communications, a leading peer-reviewed scientific journal. To date, Brilacidin has demonstrated varying degrees of antifungal activity, both in vitro and in vivo, in 14 of 19 "priority" fungal pathogens identified by the World Health Organization, with research ongoing in collaboration with NIH/NIAID-affiliated researchers and other academic groups. "There is a critical need for new antifungal agents," commented Gustavo H. Goldman, Professor of Molecular Biology, at the University of Sao Paulo, Brazil, and a Chief Editor for Frontiers in Fungal Biology. "The clinical utility of currently available antifungal treatments is limited due to emerging drug resistance, toxicity, fungistatic and not fungicidal properties, as well as drug interaction concerns. Brilacidin's ability to potentiate marketed antifungals, such as caspofungin, in multiple human pathogenic fungi, while showing strong stand-alone potency against the hard-to-treat fungal pathogen, C. neoformans, clearly supports Brilacidin's potential to be developed as a novel antifungal. Myself, along with team members, are looking forward to exploring Brilacidin's direct antifungal activity and possible favorable modulation of the host response following infection."

08:18 EDT Vincerx Pharma presents preclincal data on VIP236 - Vincerx Pharma presented a poster of preclinical data of VIP236 monotherapy treatment in PDX and metastatic PDX mouse models across several tumor types at the 2023 American Association for Cancer Research Annual Meeting. VIP236 is a first-in-class SMDC with a tailored design to efficiently treat patients with aggressive and metastatic cancer. VIP236 binds to activated alphaVbeta3 integrin, allowing specific homing to the tumor, and is efficiently cleaved by neutrophil elastase. Both proteins are present in the tumor microenvironment, are highly expressed in advanced metastatic tumors, and are associated with poor prognosis. Anticancer activity occurs after a specific and targeted release of an optimized CPT payload by NE in the TME. Once the optimized CPT payload penetrates and accumulates in the cell, it inhibits topoisomerase 1, causing DNA damage and leading to cell death. The novel optimized CPT payload of VIP236 was designed for high permeability with low active efflux potential to overcome transporter-mediated resistance observed with SN38, the active metabolite of irinotecan, which is also a CPT. Poster presentation, titled, VIP236: A small molecule drug conjugate with an optimized camptothecin payload has significant activity in patient-derived and metastatic cancer models, presented by Beatrix Stelte-Ludwig, Ph.D., Vincerx Pharma GmbH, Monheim, Germany, include: In an orthotopic metastatic breast cancer PDX model, immunohistochemistry analysis revealed an increase of alphavbeta3 and elastase staining after VIP236 treatment, while TOP1 expression remained stable. These results suggest VIP236 has potential antineoplastic activity across various advanced and metastatic cancers The mechanism of action of VIP236's optimized CPT is characterized by TOP1 inhibition, which leads to DNA damage and, ultimately, cell death. DNA damage can be measured by phosphorylation of H2Ax. Time- and treatment-dependent phosphorylation of H2Ax cells from the SNU16 cell line derived mouse model confirmed on-target TOP1 inhibition from the liberated optimized CPT payload derived from VIP236 and subsequent DNA damage. VIP236 was efficacious in a PDX non-small cell lung cancer model, with durable CRs. Partial responses and stable diseases were observed in PDX colon, renal, and TNBC models. Additionally, VIP236 treatment induced significant tumor growth inhibition in a PDX CRC liver metastatic model and significant reduction in lung and brain metastasis in a PDX orthotopic TNBC model. The reduction of brain metastases suggests successful VIP236 penetration of the blood-brain barrier. In gastric PDX cancer models, VIP236 treatment showed significant tumor growth inhibition compared with the approved anti-HER2 ADC, ENHERTU, independent of HER2 expression levels. Similar results were observed in a cell line-derived mouse model. VIP236 is currently being evaluated in a first-in-human Phase 1 dose-escalation study in patients with advanced solid tumors,

08:17 EDT Philips announces availability of HealthSuite Imaging on Amazon Web Services - Royal Philips (PHG) announced the availability of Philips HealthSuite Imaging on Amazon Web Services (AMZN). Additionally, Philips and AWS will build on their relationship, advancing AI in healthcare by applying Foundation Models using Amazon Bedrock to accelerate the development of cloud-based generative AI applications that will provide clinical decision support, help enable more accurate diagnoses, and automate administrative tasks. The availability of Philips HealthSuite Imaging on AWS is a new addition to Philips' broad capabilities in enterprise informatics, enabling improved image access speeds, reliability, and data orchestration for radiologists and clinicians across the entire imaging workflow - from diagnosis to therapy selection, treatment and follow-up. "With healthcare systems under increasing pressure, the focus of clinicians' has shifted from technical specifications towards more efficient workflows that lead to accurate diagnoses - and that's what we are delivering here," said Shez Partovi, Chief Innovation & Strategy Officer and Business Leader Enterprise Informatics at Philips. "By shifting from on-premises to the cloud, we can leverage the security, reliability, and unmatched breadth and depth of AWS to support healthcare organizations in their mission to deliver high quality care while easing the burden on their staff."

08:15 EDT Indaptus Therapeutics receives Brazilian patent allowance for Decoy platform - Indaptus Therapeutics announces it has received a patent allowance on Application #1120150158323 from the National Institute of Industrial Property of Brazil for its Decoy immunotherapy platform. The allowed patent includes a disease agnostic independent composition claim covering the Decoy platform.

08:12 EDT Daxor to exhibit BVA-100 at MedAxiom CV Transforum Conference - Daxor Corporation will be exhibiting at the MedAxiom CV Transforum Spring'23 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 20-22, 2023. The CV Transforum conference unites cardiovascular thought leaders from across the country to transform cardiovascular care together with leading industry innovators. BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and results in a 55% reduction in length of stay when done on admission. BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost of care.

08:09 EDT Enlivex Therapeutics appoints Singer to its board of directors - Enlivex Therapeutics announced the appointment of Andrew Singer to its Board of Directors. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career.

08:08 EDT Ascent Industries appoints Bill Steckel as chief financial officer - Ascent Industries announced the appointment of Bill Steckel as chief financial officer. He succeeds Aaron Tam, who has resigned as CFO. Steckel brings to Ascent more than two decades of extensive experience in operational finance, financial planning and analysis and treasury across a wide range of industries, as well as expertise in capital markets and M&A. Prior to joining Ascent, he spent over five years in multiple CFO assignments for manufacturing, distribution and technology companies. During these executive assignments, Mr. Steckel was tasked with leading a variety of transformative efforts, including building out multiple finance organizations, developing operational metrics to improve sales and enhance profitability, carving out and restructuring operating segments, implementing new ERP systems and optimizing balance sheets.

08:08 EDT Ascent Solar launches new space hardware development kits - Ascent Solar Technologies announced that it is launching a new line of easy to integrate Space Hardware Development Kits, HDKs, at the Space Foundation Space Symposium in Colorado Springs, Colorado from April 17-20, 2023. "Balancing spacecraft cost, power, mass, and delta-v budgets often presents a challenge for space mission managers. Ascent now simplifies this process with our new range of Space HDKs, an innovative space power generation solution that takes a holistic approach to maximizing benefits to the mission, and its budget constraints, instead of optimizing to a subsystem component requirement," said Julian Miller, Business Development Manager of ASTI. "The Space HDKs are designed for missions of today and the future and include cubesat, smallsat, and electric propulsion optimized arrays that provide both vehicle mass savings and increased performance. Ascent is also developing even higher power, higher voltage, and more efficient space HDKs to serve the next generation of space missions."

08:07 EDT DexCom commends expansion of CGM Medicare to diabetics using all insulin types - Dexcom commends the expansion of CGM Medicare coverage to include people with diabetes using all types of insulin, as well as certain non-insulin-using individuals who have a history of problematic hypoglycemic events. The updated Medicare policy is the biggest single expansion of CGM coverage in the U.S. to date. Dexcom G7 sends real-time glucose readings automatically to a compatible smart device or Dexcom receiverSection, no painful fingersticks required ."This landmark CMS decision has the potential to bring Dexcom CGM to millions more Medicare patients living with diabetes," said Teri Lawver, executive vice president and chief commercial officer at Dexcom. "Our MOBILE study, which helped lead to this decision, is part of Dexcom's ongoing efforts to help increase access to the most accurate, easy to use CGM technology that offers people a better way to manage diabetes and improve their quality of life." Results from the 2021 MOBILE study, sponsored by Dexcom and using Dexcom CGM, served as the primary piece of clinical evidence that led to this coverage expansion by demonstrating that CGM use significantly improves A1C and increases time in range for adults with Type 2 diabetes on basal insulin. This is a major win for the diabetes community, and another validation of how CGM can benefit all people living with diabetes," said Thomas Martens, MD, internal medicine physician and key MOBILE study investigator. "The evidence is clear: Real-time CGM use helps people with diabetes on all types of insulin, not just mealtime insulin, achieve better glycemic outcomes. This CMS decision is an important step forward in improving access to CGM technology, and we hope private insurers will follow."

08:06 EDT MIND Technology's Seamap unit receives $6.5M in orders - MIND Technology announced that its Seamap unit has received orders from international seismic contractors for GunLink source controller systems, BuoyLink GNSS systems, as well as related spares and ancillary items. The orders total approximately $6.5M and are expected to be delivered in fiscal 2024.

08:05 EDT Asset Entities appoints Jeff Blue as head of entertainment - Asset Entities signed an agreement with Jeff Blue to become the new Head of Entertainment for Asset Entities. Jeff Blue is a multi-platinum music producer, A&R executive, songwriter, author and journalist, platinum-selling music supervisor and publisher, manager, and film/tv producer.

08:04 EDT Candel Therapeutics receives FDA fast track designation for CAN-2409 - Candel Therapeutics announced that the U.S. Food and Drug Administration, FDA, granted fast track designation for its lead asset CAN-2409, an investigational viral immunotherapy, plus valacyclovir in combination with pembrolizumab in order to improve survival or delay progression in patients with stage III/IV non-small cell lung cancer, NSCLC, who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy. "We are pleased with the FDA's decision to grant fast track designation for CAN-2409, which reinforces our belief that our investigational medicine has meaningful potential to treat those living with late-stage lung cancer," said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. "Despite progress made in recent years, there remains a significant unmet need for patients with lung cancer who have an inadequate response to standard of care immune checkpoint inhibitors. Fast track designation is intended to bring promising medicines to patients sooner and the receipt of this designation by the FDA reinforces our belief that CAN-2409 has the potential to improve outcomes for patients who lack other treatment options."

08:03 EDT Abbott's FreeStyle Libre obtains expanded Medicare coverage - The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections. Medicare beneficiaries with diabetes and a history of problematic hypoglycemia may also be eligible to have their FreeStyle Libre 2 system or FreeStyle Libre 14 day system covered for reimbursement. Abbott is working to get the latest-generation FreeStyle Libre 3 system added to Medicare's list of covered systems as soon as possible.

07:52 EDT Biomerica's inFoods IBS test available at Gastro Health - Biomerica announces that inFoods IBS is now available at the flagship office of Gastro Health in Miami, with plans expand into the other Gastro Health offices in the future.

07:51 EDT BriaCell presents clinical data from Bria-IMT at AACR annual meeting - BriaCell Therapeutics is presenting clinical data from its lead product candidate, Bria-IMT, summarized in four poster sessions during the 2023 American Association for Cancer Research Annual Meeting held from April 14 - 19, 2023 at Orange County Convention Center, Orlando, Florida. Poster 1 - Title: Whole cell antigen presenting immune stimulating cells for the treatment of metastatic breast cancer: Progression Free Survival is the length of time during which a patient's cancer does not get worse and is used as a key survival and efficacy measurement. PFS benefit was observed in BriaCell's combination regimen, as measured by PFS difference from a patient's previous therapy. Most patients' PFS values were similar or higher than those of their prior regimen, a positive finding that suggests better tolerability, clinical effectiveness, and survival time. Patients treated with Bria-IMT remained on treatment for a longer period of time than expected. BriaCell's patient cohort would have typically experienced shorter time on therapy with each subsequent line of treatment, given their advanced cancer stage. Survival Update: Of 18 patients recruited since the study reopened in 2021, 15 remain alive. This compares extremely well with overall survival of 6.7-9.8 months in other similar studies. The data suggest a survival benefit in this group of difficult to treat patients who had failed multiple prior treatments and who had a typical life expectancy of 6 months or less. Anergic vs. Non-Anergic Patients: Cancer cells, which can actively weaken the immune system, thus avoid being detected by the patient's immune system, allowing them to grow and spread. This is a particularly pronounced problem in anergic patients who have very weak immune systems. Delayed-type hypersensitivity test was used to determine immune responses to Bria-IMT as a measure of immune system activation/boost in patients treated with BriaCell's combination regimen. 15 out of 27 evaluable patients from BriaCell's combination study were anergic. Following the treatment with the Bria-IMT combination regimen, 70% of anergic patients and 89% of non-anergic patients showed immune system activation/boost. The Bria-IMT regimen activated/boosted the immune system and produced clinical benefit in both non-anergic and anergic patients with more clinical benefit in patients who developed an immune response to Bria-IMT. These observations are particularly meaningful for anergic patients with weakened immune systems who have failed to respond to multiple prior treatments. Hormone Receptor Positive Patients: Survival and clinical benefits were observed across multiple subtypes of advanced metastatic breast cancer patients, especially in patients with hormone receptor positive cancer, a very large segment of the patient population. No immunotherapies have been shown to work in this group of patients. 8 out of 17 HR+ patients experienced progression-free survival benefits in the BriaCell combination study. More positive data is expected as current patients continue to remain in our study, and new patients are being enrolled. Poster 2 - Title: Engineering semi-allogeneic whole cancer vaccines with enhanced immunogenicity for the treatment of advanced solid tumors: BriaCell has developed Bria-OTS2.0 or Bria-APTC, the next generation of Bria-OTS, BriaCell's off-the-shelf personalized immunotherapy for advanced metastatic breast cancer. It expresses other immune activating cytokine molecules in addition to its immune boosting granulocyte-macrophage colony-stimulating factor. As expected, Bria-OTS2.0 was significantly more effective than Bria-OTS in activating naive T-cells, potentially suggesting faster acting mechanisms of action and better potency. Bria-OTS2.0 may deliver significant clinical efficacy and survival benefits in advanced metastatic breast cancer for the following reasons: Dual mechanisms of action to achieve strong immune response and clinical activity: The unique mechanism of action allows both direct activation of T-cells, and indirect activation of the immune cells for a more potent and faster acting anti-tumor activity. BriaCell continues to develop Bria-OTS2.0 to enhance the potency of the initial version of Bria-OTS which is planned to be used in its upcoming phase I/IIa clinical study. The pre-made design should allow fast and cost-effective treatment of patients within days following a simple, rapid, and inexpensive HLA typing saliva test. Poster 3 - Title: Tumor macrophage fusion cells detected in the circulation of metastatic breast cancer patients is prognostic for rapid progression and death; Poster 4 - Title: Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer.

07:38 EDT Camping World increases California location count with All Seasons RV Yuba City - Camping World Holdings announced an agreement to acquire All Seasons RV Yuba City, California. The acquisition is anticipated to close in the third quarter of 2023 and will increase the Company's California location count to twenty-one. Marcus Lemonis, CEO and Chairman of Camping World commented, "All Seasons RV has been proudly serving the Northern California market for over 30 years, and this acquisition further solidifies our position as the number one RV retailer by new unit volume in California, one of America's largest RV markets."

07:36 EDT Osino Resources provides update on drill programs at Ondundu Gold Project - Osino Resources provides an update on the recently completed infill and scissor hole drill programs at the Ondundu Gold Project including the best intercepts recorded in the Company's history. Dave Underwood, Osino's VP Exploration commented: "The infill drilling program at Ondundu is producing exciting results which complement and expand on previous drilling at Razorback by B2Gold in 2016. The wide intercepts at good grades confirm the robust nature at Razorback with hole ONRC23-017 being the best intercept Osino has had anywhere in Namibia. Two scissor holes were drilled westwards to check for extensional veins at right angles to the resource drilling. Not only did these holes confirm the presence of previously unknown extensional veins, but also intersected new zones of mineralization to the east of the resource in an area never previously drilled due to difficult access. This new eastern zone will be drilled out when the resource upgrade drilling gets underway." Ondundu is a sedimentary hosted, structurally controlled orogenic gold deposit located 130km to the north-west of Osino's flagship Twin Hills Gold Project. The Project has a long history of mining and exploration, most recently by B2Gold who drilled 122 DD and RC holes during the period 2016 until 2021. Osino completed the acquisition of Ondundu from B2Gold on July 21, 2022 and on October 27, 2022 announced a maiden mineral resource estimate for Ondundu comprising 26 million tonnes at an average grade of 1.13g/t Au for a total of 0.9 million ounces of gold in the Inferred mineral resource category. These mineral resources are compliant with National Instrument 43-101-Standards of Disclosure for Mineral Projects and are disclosed in the Company's current technical report entitled, Ondundu Gold Project, Namibia, NI 43-101 Technical Report, dated effective October 7, 2022. Osino's recent Ondundu drill program was designed to upgrade the mineral resource around Razorback and conduct an orientation program to optimize drilling and assay methodology. Two scissor holes were drilled to check the

07:34 EDT Titan Medical provides bi-weekly MCTO status update - Titan Medical is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders. On March 22, 2023, and as further updated on April 3, 2023, the Company announced that under NP 12-203 it had applied to the Ontario Securities Commission requesting a management cease trade order be imposed in respect of the late filing of its annual financial statements, the related management's discussion and analysis and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended December 31, 2022. The MCTO was granted by the OSC on April 3, 2023. The Company continues to work closely with its auditor and expects to file the Annual Filing Documents on or about May 19, 2023. The MCTO restricts all trading in and all acquisitions of the securities of the Company, directly or indirectly, by the Chief Executive Officer and the Chief Financial Officer of the Company until two full business days following the receipt by the OSC of the Annual Filing Documents and any other filings the Company is required to make under Ontario securities laws, or upon the further order of the director of the OSC. The MCTO does not affect the ability of shareholders who are not named in the MCTO to trade their securities. Other than a change in the number of its employees it retains, which now are 12, the Company confirms that: there are no material changes to the information contained in the Default Announcement; the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203; there has not been any other specified default by the Company under NP 12-203. The Company is working to complete the Annual Filing Documents and there is no material information concerning the affairs of the Company that has not been generally disclosed. The Company will continue to issue bi-weekly default status reports as required.

07:33 EDT Regeneron announces retirement of board chair - Regeneron Pharmaceuticals (REGN) announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company's Board of Directors and will not stand for reelection at the Company's 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 and will complete his current term through the conclusion of the Annual Meeting on June 9, 2023. Effective upon the conclusion of that meeting, the Board plans to appoint Leonard Schleifer, M.D., Ph.D., and George Yancopoulos, M.D., Ph.D., as Co-Chairs of the Board, in addition to their roles as President and Chief Executive Officer and President and Chief Scientific Officer, respectively. The Board also plans to appoint current director Christine Poon as the Lead Independent Director of the Board. Dr. Schleifer served as Chair before Dr. Vagelos joined the Company. Dr. Vagelos is the former President, Chief Executive Officer, and Chair of the Board of Merck & Co. (MRK), and is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society. Dr. Vagelos earned his Bachelor of Science degree in chemistry from the College of Arts and Sciences at the University of Pennsylvania and attended medical school at the Columbia University School of Medicine.

07:32 EDT Phio Pharmaceuticals reports preclinical data on anti-tumor candidate PH-762 - Phio Pharmaceuticals announced that in vivo data from a hepatocellular carcinoma model provides insight into the mechanism by which locally administered mouse-targeted PH-762 exerts systemic anti-tumor efficacy, or abscopal effect. In the study, intratumoral administration of mPH-762 stimulated a local anti-tumor immune response and generated systemic tumor-reactive memory T cells, suggesting that the abscopal effects of PH-762 are mediated by the immune system. PH-762 is under clinical development in a phase 1b trial for neoadjuvant treatment of advanced resectable melanoma.

07:32 EDT Momentus advances through MET in-space testing campaign - Momentus continues to advance through its Microwave Electrothermal Thruster, or MET, in-space testing campaign, completing more than a dozen test firings ranging from 30 seconds up to five minutes - the expected range for Momentus standard missions.

07:26 EDT Enzolytics to sell Biogenysis, Virogentics to Sagaliam Acquisition for $250M - Enzolytics and Sagaliam Acquisition have executed a non-binding term sheet for the sale of Biogenysis and Virogentics, operating subsidiaries of Enzolytics. The value of the transaction is $250,000,000 The definitive agreement is being finalized with an expected closing date of May 19, 2023. Under the terms of the agreement, BGEN and VIRO will become wholly owned subsidiaries of Sagaliam, currently trading on NASDAQ, and will adopt SAGA Scientific Holdings Corp. as the corporate name. The transaction, once completed, will provide BGEN and VIRO with significant additional capital to continue their development and expansion of existing and future technology platforms. In addition, Sagaliam expects to raise additional capital through a private investment in public equities. The anticipated capital raise from the PIPE is expected to be primarily used by BGEN and VIRO to pay transaction-related expenses and fund the clinical trials of ITV-1, marketing of IPF Immune, production of fully human monoclonal antibodies and continued advancement in its proprietary technology involving the application of Artificial Intelligence in therapeutic discoveries and production.

07:21 EDT Diversified Royalty reports Q1 SSS growth of 17.6% for Mr. Lube stores - Diversified Royalty announces the preliminary results for its royalty partners for the three months ended March 31, 2023. Mr. Lube Canada Limited Partnership generated same-store-sales-growth of 17.6% for the Mr. Lube stores in the royalty pool for Q1 2023, compared to SSSG of 16.3% for the three months ended March 31, 2022. DIV expects to report that aggregate royalty income and management fees of $5.8 million were generated from Mr. Lube in Q1 2023, an increase of 19.7% compared to Q1 2022. The increase was due to strong SSSG as well as the addition of 4 net new stores to the Mr. Lube royalty pool on May 1, 2022. DIV expects to report that royalty income from SBS Franchising was $2.0 million for Q1 2023. DIV granted Stratus the license to use the Stratus rights in exchange for an annual royalty payment of US$6.0 million increasing each November at a rate of 5% in 2023, 2024, 2025 and 2026 and 4% per year thereafter. DIV expects to report that the royalty entitlement to DIV from Nurse Next Door Professional Homecare Services was $1.3 million in Q1 2023. The DIV Royalty Entitlement from Nurse Next Door grows at a fixed rate of 2.0% per annum during the term of the license, with the most recent increase effective October 1, 2022. Oxford locations in the Oxford royalty pool generated SSSG of 15.8% in Q1 2023, compared to SSSG of 14.2% in Q1 2022. DIV expects to report that royalty income and management fees of $1.2 million were generated from Oxford Learning Centres in Q1 2023, compared to $1.0 million in Q1 2022. This strong growth is representative of the increased demand for Oxford's tutoring services. DIV expects to report royalty income and management fees of $1.1 million were generated from Sutton Group Realty Services in Q1 2023, compared to $1.1 million in Q1 2022. The fixed royalty payable by Sutton increases at a rate of 2.0% per year, with the most recent increase effective July 1, 2022. DIV expects to report royalty income of $1.1 million from AIR MILES in Q1 2023, which is down 26.4% compared to Q1 2022. DIV's royalty payment is derived from several AIR MILES metrics, with AIR MILES reward miles issued being the primary metric, and other metrics including AIR MILES reward miles redeemed, service revenue, commissions, and promotional items, all of which affect quarterly variability. The primary reason for the decrease in royalty income is the exit of Sobeys from the AIR MILES Reward Program on a region-by-region basis between mid-August 2022 and Q1 2023. As previously disclosed in DIV's news release dated March 10, 2023, the Bank of Montreal has entered into a purchase agreement with LoyaltyOne to acquire the Program from LoyaltyOne. The sale is subject to the approval of the court as part of LoyaltyOne's proceedings under the Companies' Creditors Arrangement Act Canada . SSSG in Q1 2023 for the Mr. Mikes restaurants in the royalty pool was 30.5% compared to Q1 2022. DIV expects to report that royalty income and management fees of $1.0 million were generated from Mr. Mikes in Q1 2023, which excludes approximately $0.05 million from the partial payment of deferred contractual royalty fees and accrued management fees, compared to $0.7 million in Q1 2022. The Q1 2022 performance of the Mr. Mikes restaurants in the royalty pool was negatively impacted by vaccine and mask mandates and other government restrictions related to the COVID-19 pandemic which remained in place for all or a portion of such quarter in various provinces.

07:16 EDT Medicenna presents preclinical IL-13 Superkine therapies data at AACR meeting - Medicenna Therapeutics announced that new preclinical data characterizing the Interleukin 13 Superkines, MDNA132 and MDNA213, and a series of next generation IL-13 Superkine therapies, were presented at the 2023 Annual Meeting of the American Association for Cancer Research, AACR, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 - 19, 2023. "Our IL-13 Superkines have been engineered to target the IL-13 decoy receptor, IL-13Ralpha2, which is overexpressed in several solid tumors but minimally expressed in normal tissues, making it an attractive target for immunotherapies," said Fahar Merchant, Ph.D., President and CEO of Medicenna. "Tumors that express high levels of IL-13Ralpha2 are known to be aggressive, resulting in poor survival outcomes for cancer patients. The data presented at AACR demonstrates the ability of our IL-13 Superkines to preferentially accumulate in the microenvironment of IL-13Ralpha2-expressing tumors, enabling development of first-in-class precision immunotherapies that can selectively deliver a variety of therapeutic payloads. These IL-13 Superkine fusions are designed to address unmet needs for cancer patients with tumors that do not respond to blockbuster immunotherapies." The AACR poster includes data demonstrating that both MDNA132 and MDNA213 exhibit highly selective binding to the IL-13 decoy receptor and, in a murine model, selectively accumulate in the tumor microenvironment for several days.

07:15 EDT Helius Medical showcasing PoNS device at AAN annual meeting - Helius Medical Technologies announced it will exhibit at the American Academy of Neurology Annual Meeting for the first time since its Portable Neuromodulation Stimulator device became commercially available in both the United States and Canada. Helius's presence at the conference comes at a time when PoNS is seeking additional indications for neurological conditions that lead to gait and/or balance impairment. The U.S. Food and Drug Administration authorized PoNS to be used for therapeutic management of gait deficit due to multiple sclerosis, as well as a Breakthrough Devices Designation in stroke. Health Canada authorized PoNS for short-term treatment of balance and gait deficit due to MS, mild-to-moderate traumatic brain injury and, in the past month, stroke. Visitors to the 75th AAN Annual Meeting - held April 22-27, 2023, at the Boston Convention and Exhibition Center - have the opportunity to interact with Helius's medical team members, and learn more about PoNS mechanisms of action and therapeutic benefits in these indications by stopping at booth 1685.

07:14 EDT BoROSE Lifescience launces TeaPot in the Quebec market - ROSE LifeScience, majority owned by Village Farms International (VFF) announced the launch of cannabis-infused iced tea beverage 'TeaPot' in the Quebec market. As part of its existing partnership with Entourage Health (ETRGF), ROSE has commercialized and distributed the sativa lemon black iced tea beverage. The new beverage is now available to consumers at Societe quebecoise du cannabis stores and on its website. The launch of 'TeaPot' is an extension of the work between Entourage and the Boston Beer Company (SAM) who partnered in 2021 to develop the innovative line of cannabis-infused beverages in Canada. "Securing entry into Quebec, one of Canada's most populated provinces, alongside a well-reputed local partner in ROSE, we are excited to expand our distribution footprint," said George Scorsis, CEO and Executive Chairman, Entourage. "Our partners at Boston Beer Company have a history of producing some of North America's most beloved craft beverages and TeaPot is no exception. The cannabis-infused beverage has been well received since its initial launch last summer in Canada and we are confident this will continue as we introduce TeaPot to Quebecers."

07:12 EDT Danimer, TotalEnergies Corbion develop new compostable coffee pod biopolymer - Danimer Scientific (DNMR) and TotalEnergies Corbion (TTE) announced that they have developed a new compostable coffee pod biopolymer that is in compliance with proposed EU packaging regulations. The EU recently announced a proposal requiring plastic packaging such as tea bags, coffee pods, very light plastic bags and sticky labels for fruit and vegetables to be compostable. Danimer and TotalEnergies Corbion's new formulations, containing a blend of Danimer's signature polyhydroxyalkanoate, or PHA, Nodax and TotalEnergies Corbion's Luminy High Heat polylactic acid material, have already passed biodegradability tests and have been certified by TUV as home compostable. They are currently being tested in the market by numerous European companies.

07:11 EDT Regeneron aflibercept, EYLEA Injection to be featured at ARVO 2023 meeting - Regeneron Pharmaceuticals (REGN) and its collaborator Bayer (BAYRY) announced that aflibercept 8 mg and EYLEA Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology, ARVO, 2023 Annual Meeting from April 23-27. Among the presentations will be new subgroup data and further analyses of aflibercept 8 mg treatment from the pivotal PULSAR and PHOTON trials in wet age-related macular degeneration, wAMD, and diabetic macular edema, DME, as well as the Phase 2 CANDELA trial in wAMD. "Our data presentations at ARVO build on the more than 20 years of industry-leading knowledge and dedicated research aimed at addressing the unmet needs of patients with serious retinal diseases," said Boaz Hirshberg, M.D., Senior Vice President, Clinical Sciences General Medicine at Regeneron. "We look forward to sharing presentations on the efficacy and safety of EYLEA in multiple retinal diseases, as well as additional analyses of the pivotal aflibercept 8 mg trials - all of which reinforce our unwavering commitment to advancing retinal care for patients at risk of losing their vision."

07:09 EDT Moving iMage awarded contracts from three universities - Moving iMage announced it was awarded projection and sound technology upgrade projects from three universities.

07:07 EDT Aditxt says unit Pearsanta submitted bid to acquire all of Lucira Health assets - Aditxt is pleased to provide an important update regarding its three innovation programs and strategic M&A initiatives. On April 3 Aditxt subsidiary, Pearsanta submitted a bid to acquire substantially all of Lucira Health (LHDXQ) assets, which included Lucira Connect and FDA-approved at-home combination COVID-19 and flu tests. At the bankruptcy auction, which was held on April 6 Pearsanta was chosen as the backup bidder. On April 11 , Aditxt filed an objection to the sale of the assets of Lucira to the winning bidder, raising issues as to the fairness and the good faith of Lucira, as well as questioning value maximization for creditors. However, Pearsanta was ultimately designated as the backup bidder. Takeaway: "The interest in the Lucira assets at auction shows the sheer value of the test-to-treat model," said Amro Albanna, co-founder, chairman and CEO of Aditxt and current acting CEO of Pearsanta. "Adixt's mission is to advance innovations that allow people to make better, smarter, more informed decisions about their health based on more insightful data. The technology that we've already invested in-along with the therapeutics in our portfolio-mirror our mission of innovation

07:07 EDT Algonquin Power backs FY23 adjusted EPS view 55c-61c, consensus 59c - AQN's previously-disclosed estimate of adjusted net earnings per common share for the 2023 fiscal year within a range of 55c to 61c remains unchanged. AQN expects to release its first quarter financial results on Thursday, May 11, before market open.

07:05 EDT Algonquin Power, American Electric terminate stock purchase agreement - Algonquin Power (AQN) announced that Liberty Utilities, an indirect subsidiary of AQN, has mutually agreed with American Electric Power (AEP) to terminate the stock purchase agreement regarding Kentucky Power Company and AEP Kentucky Transmission.

07:04 EDT Trillium Capital outlines path for revenue growth for Getty Images - Trillium Capital announced that it has outlined a path for revenue growth for Getty Images Holding. "The principals of Trillium Capital LLC own over 500,000 shares of common stock and common stock equivalents of Getty. We believe that the Board of Directors of Getty has a fiduciary responsibility to maximize shareholder value for all stockholders. Stewardship of a public company is an important responsibility for a Board. This includes things such as selecting the right executive team, working with management to define the strategic path, building a sustainable and growing franchise and most of all creating value for all stakeholders. Some of the points in our path to revenue growth for Getty are the following ideas: Expand partnership with Nvidia using their rendering capabilities/technology and leveraging Getty's deep metadata/tagging system (potential strategic buyer). Create a strategic relationship with Microsoft & Bing through their Open API system (potential strategic buyer). Create a strategic relationship with Adobe to combine with their extensive imaging collection (potential strategic buyer). Build a metadata relationship with Facebook and Instagram to upload digital photos and videos (potential strategic buyer). Build relationships with universities for students to upload and share photography and videos with large family and friend groups using Artificial Intelligence and Metadata. Expand the platform to upload photos and videos from such things as special events like sports, religious ceremonies or churches, museums, libraries, weddings, graduations, and family events. Partner with magazines and newspapers such as National Geographic, People Magazine, New York Times, The Washington Post, etc. to upload and download digital libraries. The above are just some of our preliminary steps on the path to create massive revenue growth for Getty. We continue to believe that our Managing Partner, Scott Murray, should be appointed to the Board. We are confident that many more great growth and strategic plans will come to the surface once he joins the Board."

07:03 EDT KAR Auction names Brad Lakhia CFO - KAR Auction (KAR) announced the company has named Brad Lakhia EVP and CFO. Lakhia will be responsible for leading all financial and reporting functions across KAR, as well as investor relations and the company's capital investment strategy. Lakhia also joins KAR's executive committee and will report to KAR Global CEO Peter Kelly. Lakhia brings more than 25 years of experience including treasury, financial planning and analysis, business development, mergers and acquisitions, and operational finance within large and complex companies. Most recently, he served as VP Finance, Americas for The Goodyear Tire (GT), the company's largest business unit representing over $10B in revenue.

07:02 EDT Bristol-Myers granted three applications for myeloma candidate Abecma - Bristol Myers (BMY) and 2seventy bio (TSVT) announced that the FDA has accepted the companies' supplemental Biologics License Application for Abecma with the KarMMa-3 study that investigated the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The FDA has assigned a Prescription Drug User Fee Act goal date of December 16. The European Medicines Agency has also validated Bristol Myers Squibb's Type II variation application for Abecma based on the KarMMa-3 study. Validation of the application confirms the submission is complete and begins the procedure and scientific assessment. In addition, Japan's Ministry of Health, Labour and Welfare has accepted Bristol Myers Squibb's supplemental New Drug Application for Abecma based on the KarMMa-3 study. The three regulatory applications were based on interim results from the KarMMa-3 study evaluating Abecma compared with standard combination regimens. Results showed treatment with Abecma demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and overall response rate, and safety results were consistent with the well-established and generally predictable safety profile of Abecma.

07:01 EDT Amarin names Berg interim President, CEO - Amarin announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer. In addition, the board has appointed Oliver O'Connor as a new independent Director of the company. Both appointments are effective immediately. Berg joined Amarin in November 2012 and has more than 25 years of biopharmaceutical industry experience.

07:01 EDT EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 13,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on April 14, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $4.33 per share, the closing price of EyePoint Pharmaceuticals' common stock on April 14, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

06:49 EDT Target Hospitality acquires strategic assets - Target Hospitality announced it has acquired strategic assets focused on increasing portfolio capacity in support of the United States government's critical humanitarian aid mission. These geographically significant assets have been utilized by the United States government to support a variety of humanitarian housing solutions across government agencies. Target believes the strategic location of these assets, along with its suite of hospitality solutions, positions the company to expand its service offerings supporting the U.S. government's evolving and dynamic humanitarian mission. The company said, "Including Target's existing humanitarian community, the addition of these assets will allow the Company to react quickly and support the government's stated and urgent need for additional housing capacity. This urgent and compelling need is a result of the anticipated substantial increase of individuals crossing the U.S. Southwest boarder following the cessation of Title 42, anticipated in May of 2023, resulting in meaningful excess demand for existing government humanitarian solutions. This transaction is a continuation of the Company's strategy to pursue high return capital allocation initiatives, including expanding reach across government agencies, while strategically aligning network capabilities with growing government end-market demand."

06:48 EDT Independence Drilling chairman Daniel McNease retires, James Minmier succeeds - Independence Contract Drilling announced that Daniel McNease has retired from the company's board of directors, effectively immediately, for personal reasons. McNease served on the company's board of directors since 2012 and served as chairman of the board since 2019. The board has selected James Minmier to replace McNease as chairman of the board. Minmier has served as director of the company since 2018. The board has elected Brian Berman to the board of directors to fill the vacancy created by McNease's departure.

06:35 EDT Primo Water announces resolution of litigation with Legion Partners - Primo Water announced that it has agreed to a proposal of settlement offered by Legion Partners dismissing Legion's Application in the Ontario Superior Court of Justice. Both parties have agreed to bear their own litigation expenses. Pursuant to the settlement, the company has exercised its discretion under Primo Water's Bylaws to waive any deficiencies in the nomination notice submitted by Legion with respect to Legion's nominees Henrik Jelert and Lori Tauber Marcus, such that all four of Legion's nominees will now be permitted to stand for election to the company's board of directors at the rescheduled 2023 annual and special meeting of shareowners. The board took this compromise action to avoid the ongoing and significant expense and distraction associated with litigation and determined that resolving the outstanding litigation was in the best interests of the company and its shareowners. In order to allow shareowners sufficient time to consider the business of the annual meeting and to review the backgrounds of each of the nominees, and consistent with the settlement agreement, the board has set a new date for the annual meeting of May 31 at which shareowners of record as of April 27 will be entitled to vote. Primo Water will be mailing shareowners a revised proxy statement and a new blue proxy card. Any previously submitted proxies will be discarded and shareowners will be required to resubmit their votes.

06:32 EDT Vaxcyte reports 'positive' results from Phase 2 study of VAX-24 - Vaxcyte announced positive results from the VAX-24 Phase 2 study in adults aged 65 and older, as well as data from the full six-month safety assessment and prespecified pooled immunogenicity analyses from both the Phase 2 study in adults aged 65 and older and the prior Phase 1/2 study in adults aged 18-64. VAX-24, the company's lead, broad-spectrum 24-valent pneumococcal conjugate vaccine candidate, is being studied for the prevention of invasive pneumococcal disease. In the Phase 2 study in adults aged 65 and older, VAX-24 demonstrated robust OPA immune responses for all 24 serotypes at all doses studied, confirming the prior adult study results. The VAX-24 2.2mcg dose, which Vaxcyte plans to advance to Phase 3, showed an overall improvement in immune responses vs. PCV20 relative to the results from the prior Phase 2 study in adults aged 50-64. The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.

06:08 EDT Hive Blockchain reports March production of 282 Bitcoins - Hive Blockchain (HIVE) reported production figures from the company's global Bitcoin (BTC) operations for the month of March 2023, with 282 Bitcoin produced, and a current BTC HODL balance of approximately 2,310. On average the company has continued to operate above 3 Exahash throughout March 2023. HIVE produced 282 Bitcoin in the month of March 2023, from ASIC and GPU mining operations, representing an average of 91 Bitcoin Per Exahash, with an average hashrate of 3.09 EH/s; produced an average of 9.1 BTC per day in March 2023; has received over 5,600 BuzzMiners in its data centers, all of which are operating as of today; ended the month with 3.36 EH/s of mining capacity, including ASIC and GPU BTC hashrate; sold all of the Bitcoin earned from GPU mining hashrate payouts. The Bitcoin network difficulty was 43.1T as at March 1, and increased to 46.8T as at March 31, reaching an all-time high. Accordingly, Bitcoin mining difficulty ended the month about 9% higher than the beginning of the month. As more people mine Bitcoin, difficulty increases, Hive will self-curtail part of its operations if the unhedged spot energy prices are uneconomical, thereby leaving part of its total gross hashrate unutilized.

06:05 EDT GoGreen Investments extends deadline to complete initial business combination - GoGreen Investments has issued a promissory note in the principal amount of up to $2,760,000 to GoGreen Sponsor 1 LP and Lifezone, which have deposited an aggregate amount of $2,760,000 - representing 10c per public share - into the company's trust account for its public stockholders. The Extension Loan enables the company to extend the date by which the company must complete its initial business combination from April 25 to July 25. The Extension is the second of two three-month extensions permitted under the company's governing documents. The proceeds of the Extension Loan will be held in the Trust Account and used to fund any redemptions of the company's public shares. If the company does not complete an initial business combination by the Extended Date, the Extension Loan will be repaid exclusively from funds held outside of the Trust Account.

06:03 EDT Sigma Lithium achieves first production of Green Lithium - Sigma Lithium announced that it has achieved first production of Green Lithium, thus concluding the commissioning process and transitioning the company from developer to producer. Completing the commissioning of the Phase 1 Greentech Plant is the final critical milestone in the development of the Grota do Cirilo project in Brazil and marks the successful completion of Phase 1 project construction. Sigma Lithium's technical team, led by COO Brian Talbot, will now turn its attention to ramping up throughput to full production capacity, which it expects to achieve by July. As the project ramps to full production capacity, high-quality Green Lithium will be stockpiled and prepared for sale, with an inaugural first shipment of approximately 15,000 tons expected in May. The company recently announced that it had obtained its environmental operating license to sell all Green Lithium product from current and future production, including any stockpiled product. Ana Cabral-Gardner, Sigma Lithium CEO and co-chairperson congratulates the Sigma Lithium team and is pleased that Sigma Lithium is delivering on its production targets for all of its stakeholders.

06:01 EDT ZeroFox to acquire LookingGlass for $26M - ZeroFox announced a definitive agreement to acquire LookingGlass Cyber Solutions, a company in external attack surface management and global threat intelligence. Under the terms of the agreement, ZeroFox will acquire LookingGlass for approximately $26M, primarily in stock (9.4M shares), combined with convertible debt and cash, subject to purchase price adjustments and performance earnouts. The acquisition is expected to close within the next 30 days. ZeroFox will provide additional guidance during the Q1 FY24 earnings call.

05:22 EDT Apple opens first Apple Store in India - Apple's first retail location in India is one of the company's most sustainable stores yet, offering Today at Apple sessions featuring local artists and creatives, with a team of more than 100 ready to provide exceptional service for customers Apple previewed Apple BKC, the first Apple Store in India. Located in Mumbai's bustling Bandra Kurla Complex financial, arts, and entertainment district, Apple BKC will serve as a dynamic space where customers can come together, explore Apple products and services, enjoy exceptional service, and learn how to get more out of their devices through free Today at Apple sessions.

05:14 EDT Argenx, Genmab enter collaboration agreement to develop therapeutic antibodies - Argenx (ARGX) and Genmab (GMAB) announced that they have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer. As per the agreement, Argenx and Genmab will each have access to the suites of proprietary antibody technologies of both companies to advance the identification of lead antibody candidates against differentiated disease targets. Under the terms of the agreement, Argenx and Genmab will jointly discover, develop and commercialize products emerging from the collaboration while equally sharing costs as well as any potential future profits. The collaboration will initially focus on two differentiated targets, including one within immunology and one within cancer, with the potential to expand to more.

05:09 EDT Verizon deploys zero trust network capabilities for Siemens - Verizon Business (VZ) is supporting Siemens (SIEGY) with a range of network connectivity solutions that will provide Siemens' employees at smaller office sites with a 'plug and play' user experience, whilst putting security and zero trust principles first. Siemens' Zero Trust Program ensures that all devices of Siemens' employees must be authenticated, authorized and continuously validated before access is given or retained to the company's mission critical applications and data. Verizon Business will deploy "internet only" connectivity such as a global Managed Wide Area Network, based on Cisco Meraki's technology and critical to the success of Siemens' "never trust, always verify" program.

05:03 EDT Apollo Global opens new office in London - Apollo announced the opening of a new office in London, United Kingdom. The transition to a single space in London reflects Apollo's desire to offer a workplace for its teams and expand its offering of integrated asset management and retirement services capabilities on a global basis, including across European markets.